header logo image


Page 18«..10..17181920..30..»

Archive for the ‘Molecular Genetics’ Category

Ongoing Study Reveals Key Factors that Will Drive the Growth of Biological Computers Market During 2019-2027 – Cole of Duty

Friday, May 8th, 2020

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook.

A biological computer is a special type of microcomputer that is specially designed for medical applications. It is an implantable device that is mainly used for various tasks like monitoring the bodys activities or including therapeutic effects, all at the molecular or cellular level. Biological computers are used to produce input and output, and software is composed of DNA, the material of genes, whereas DNA-manipulating enzymes are used as the hardware.

The biological computer market anticipated to grow as rising in the prevalence of cancer and an increase in demand for DNA or gene chips is some of the major factors driving the market growth. However, less awareness of this device is restraining the market growth. Nevertheless, an increase in healthcare expenditure and overall growth in the healthcare industry are influencing the market growth.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPRE00007617

Top Dominating Key Players:

1. Biometrix Technology Inc2. Emulate Inc.3. IBM4. Illumina, Inc.5. IndieBio6. Macrogen Corp7. Merck KGaA8. Microsoft9. Sequenom Inc.10. Thermofisher Scientific

The biological computers market is segmented on the basis of component, application and by end user. Based on component the market is segmented as hardware, software, input and output. On the basis of application the market is categorized as oncology, molecular genetics, nanobiotechnology and others. On the basis of end user the market is categorized as pharmaceutical & biotechnology companies, research centers, healthcare it companies, hospital & clinics and others.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in biological computers market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The biological computers market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting biological computers market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the biological computers market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPRE00007617

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

More here:
Ongoing Study Reveals Key Factors that Will Drive the Growth of Biological Computers Market During 2019-2027 - Cole of Duty

Read More...

Antibody That Blocks Coronavirus From Infecting Cells Discovered by Scientists – Newsweek

Friday, May 8th, 2020

Scientists have identified an antibody in a lab that they say can prevent the novel coronavirus from infecting cells. The team hopes the antibody could be used to create treatments for COVID-19, the disease caused by the virus.

Since the coronavirus began infecting people in the central Chinese city of Wuhan late last year, more than 3.5 million people have been diagnosed with COVID-19, over a million have recovered and almost 248,000 have died, according to Johns Hopkins University.

The team, whose research was published in the journal Nature Communications, have been exploring whether what are known as monoclonal antibodies could help patients with COVID-19. Currently there is no vaccine or specific treatment for the disease. Monoclonal antibodies are a type of protein created in a lab which can bind to a specific substance in the body. These types of antibodies mimic how the immune system responds to a threat, and are used to treat some forms of cancer.

An antibody named 47D11 was found to bind to the spike protein which the novel coronavirus, known as SARS-CoV-2, uses to enter the body, and block it in a way that neutralizes the pathogen.

To carry out their study, the researchers used mice whose biology was tweaked to create antibodies similar to those found in humans. They injected the animals with spike proteins that the viruses which cause SARS, MERS, and some types of common cold use to invade cells. These viruses are members of the large coronavirus family of pathogens which also includes SARS-CoV-2, the bug which causes COVID-19. The mice produced 51 antibodies capable of neutralizing the spike protein of the injected coronaviruses. This stage of the research was done before SARS-CoV-2 first came to the attention of health officials in late 2019.

The team later watched to see if the antibodies would neutralize SARS-CoV-2 and SARS-CoV in lab samples, and found 47D11 did.

Co-author Berend-Jan Bosch, associate professor of the Utrecht University Infection and Immunity programme, explained in a statement that the research builds on work his team had done previously on antibodies which can target SARS-CoV, the virus which causes SARS.

"Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 [the COVID-19 virus] in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus."

Co-author Frank Grosveld, Academy Professor of Cell Biology at the Erasmus Medical Center, Rotterdam, said: "This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment."

Experts not involved in the research welcomed the findings, but also pointed out the study's limitations.

Tony Carr, professor of molecular genetics in the Genome Damage and Stability Centre (GDSC) at the University of Sussex, said in a statement: "The block to infectivity is entirely based on cell culture work, but the previous literature supports the proposal that this reagent should be explored further as a potential treatment."

Penny Ward, visiting professor in Pharmaceutical Medicine at King's College London, said the antibody has the potential to be used to prevent and treat SARS-CoV-2 infection, "however without studying this in an animal model, it is not clear which of these approaches might be most efficient."

The findings would have been more robust if the team were able to show the antibody could prevent and treat COVID19 in animals, she said.

"It is not possible to conclude that the product will be effective in vivo in humans," said Ward.

Polly Roy, professor of virology at the London School of Hygiene and Tropical Medicine, said the data the team created is "very good," and highlighted they are well-known for their work on coronaviruses.

Gary McLean, professor in Molecular Immunology at London Metropolitan University, said: "Because it is not done in people and the antibody is not even found in people as far as we know there are limitations. However it is a nicely done study that could provide a potential biotherapeutic that could be used to treat COVID-19.

Read more

The research complements separate projects looking at whether a century-old technique known as convalescent plasma therapy, where the blood from a person who has recovered from COVID-19 is inserted into a current patient in the hope it will help them beat the disease.

Professor Babak Javid, principal investigator at Tsinghua University School of Medicine, Beijing, and consultant in infectious diseases at Cambridge University Hospitals in the U.K., commented: "This is a very interesting study. One of the most widely touted experimental (though not yet proven) treatments for COVID is the use of convalescent plasma."

He said: "However, use of convalescent plasma is difficult to scale and make widely available as a treatment and has some potential safety concerns since it is a blood product. Therefore there has been intense scientific interest in identifying individual antibodies that can also neutralize SARS-CoV2. This is because we are able to manufacture large quantities of individual antibodies (known as monoclonal antibodies or mAbs) at scale as a pharmaceutical treatment for COVID. Monoclonal antibodies also don't have the safety concerns of administering blood products."

Simon Clarke, associate professor in Cellular Microbiology at the University of Reading, U.K., said in a statement: "Antibodies like this can be made in the lab instead of purified from people's blood and could conceivably be used as a treatment for disease, but this has not yet been demonstrated.

"While it's an interesting development, injecting people with antibodies is not without risk and it would need to undergo proper clinical trials."

See the article here:
Antibody That Blocks Coronavirus From Infecting Cells Discovered by Scientists - Newsweek

Read More...

Coronavirus quickly spread around the world starting late last year, new genetic analysis shows – CNN Philippines

Friday, May 8th, 2020

(CNN) A new genetic analysis of the virus that causes Covid-19 taken from more than 7,600 patients around the world shows it has been circulating in people since late last year, and must have spread extremely quickly after the first infection.

Researchers in Britain looked at mutations in the virus and found evidence of quick spread, but no evidence the virus is becoming more easily transmitted or more likely to cause serious disease.

"The virus is changing, but this in itself does not mean it's getting worse," genetics researcher Francois Balloux of the University College London Genetics Institute told CNN.

Balloux and colleagues pulled viral sequences from a giant global database that scientists around the world are using to share data. They looked at samples taken at different times and from different places, and said they indicate that the virus first started infecting people at the end of last year.

"This rules out any scenario that assumes SARSCoV-2 may have been in circulation long before it was identified, and hence have already infected large proportions of the population," Balloux's team wrote in their report, published in the journal Infection, Genetics and Evolution.

That is one piece of bad news. Some doctors had hoped the virus was circulating for many months and may have quietly infected many more people than has been reported. That would offer the hope that there might be some immunity already built up in some populations.

"Everyone was hoping for that. I was too," Balloux said.

Their findings pour cold water on such an idea. At the most, 10% of the global population has been exposed to the virus, Balloux estimated.

Many different studies have shown that the new coronavirus, often called SARS-CoV-2 by scientists, originated in a bat but had to have infected another animal before it jumped into humans. The first human cases were reported in Wuhan, China, last December.

Viruses make mistakes every time they replicate themselves, and these mutations can be used as what's called a molecular clock to track a virus through time and geography.

"Our results are in line with previous estimates and point to all sequences sharing a common ancestor towards the end of 2019, supporting this as the period when SARS-CoV-2 jumped into its human host," the team wrote.

"It's very recent," Balloux said. "We are really, really, really confident that the host jump happened late last year."

That's because viral samples taken from all corners of the globe show multiple mutations, and they are similar mutations. "Everything is everywhere," the team wrote.

"It has been introduced and introduced and introduced in almost all countries," Balloux added.

They also found genetic evidence that supports suspicions the virus was infecting people in Europe, the US and elsewhere weeks or even months before the first official cases were reported in January and February. It will be impossible to find the "first" patient in any country, Balloux said.

"All these ideas about trying to find a Patient Zero are pointless because there are so many patient zeros," he said.

Balloux's team's findings were reviewed by other experts, a process called peer review, before they were published in the journal. He said some reports by other teams, published online in what are called pre-print websites, may have drawn incorrect conclusions.

"All viruses naturally mutate. Mutations in themselves are not a bad thing and there is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected. So far we cannot say whether SARS-CoV-2 is becoming more or less lethal and contagious," Balloux said.

Lane Warmbrod, an analyst at the Johns Hopkins Center for Health Security who has been tracking the reports on the genetics of the new coronavirus. She said more studies are needed in animals to demonstrate how changes in the genetics of the virus could make it more or less infectious or pathogenic.

"Just because these studies tell us these mutations are quickly spreading or becoming dominant doesn't mean anything except we know it happened. It doesn't actually tell us anything about what's happening biologically," Warmbrod told CNN.

Reports about mutations can be important for teams working on drugs and vaccines to fight the coronavirus. Vaccines, especially, need to target parts of the virus that are conserved that do not change much over time.

This story was first published on CNN.com, "Coronavirus quickly spread around the world starting late last year, new genetic analysis shows."

Go here to read the rest:
Coronavirus quickly spread around the world starting late last year, new genetic analysis shows - CNN Philippines

Read More...

Sallie Permar: Who Are Your Trusted Sources on COVID-19? – Duke Today

Monday, April 27th, 2020

As the COVID-19 pandemic continues, the question of where to turn for solid information has never been more important.

Many Duke experts are being approached now for their expertise and insight. But where do they turn for guidance and the latest information? In this ongoing series, Duke Today asks Duke experts to share their preferred sources.

Dr. Sallie Permar is a physician scientist who focuses on prevention and treatment of neonatal viral infections. A professor of immunology, pathology, pediatrics, molecular genetics and microbiology and associate dean for physician-scientist development, she recently wrote about the effect of the pandemic on medical research.

To stay abreast of how the infectious diseases field is responding to the novel coronavirus, she consults a mix of websites, podcasts and social media.

This Week in Virology, hosted by Vincent Racaniello and fellow virologists, has featured recent guest hosts who are stars of COVID-19 research, such as Drs. Daniel Griffin, Ralph Baric, Mark Denison, Stanley Perlman and Christian Drosten.

Immune, hosted by immunologists Cindy Leifer, Stephanie Langel, Vincent Racaniello, carried a recent two-part series on COVID-19 immunology with Dr. Brianne Barker that was especially compelling.

I also listen to COVID-19: Commonsense Conversations on the Coronavirus Pandemic, with host Dr. Ted OConnell, a family physician and writer.

For the latest on numbers by region, I check Johns Hopkins Universitys COVID-19 map.

COVID-19 guidelines can be found on the Centers for Disease Control website.

For the latest on viral sequence dynamics, I check gisaid.org.

For recent COVID-19 research reports, I consult bioxiv.org and medrxiv.org. The Twitter sources below provide real-time critical reviews of the newly posted manuscripts.

For the latest on epidemiology and case series reports, I consult: - the CDC Morbidity and Mortality Weekly Report and - World Health Organization situation reports.

And for compilations of the latest research I check: - Duke Pharmacist Elizabeth Dodds-Ashleys Daily Digest. - The American Association of Medical Colleges Novel Coronavirus Update by chief scientific officer and former Duke faculty member Dr. Ross McKinney. - Publons compilation of latest research manuscripts, which includes some crowd-sourced reviews.

Finally, great sources to follow on Twitter include:@NIAIDNews; @CEPIvaccines;NIH Vaccine Research Center scientist Kizzmekia Corbett (@KizzyPhD);The laboratory of UNC-Chapel Hills Dr. Ralph Baric (@Baric_Lab);The laboratory of Vanderbilt Universitys Dr. Mark Denison (@Denisonlab);Florian Krammer, an immunologist who is developing antibody assays (@florian_krammer); Virologists Dr. Benhur Lee (@VirusWhisperer) and Angela Rasmussen (@angie_rasmussen);COVID-19 drug developer Timothy Sheahan (@timothysheahan);David Martinez, a former Ph.D. student who is now testing vaccine and therapeutic antibodies in the lab of Ralph Baric (@David_RMartinez).

View post:
Sallie Permar: Who Are Your Trusted Sources on COVID-19? - Duke Today

Read More...

A gene that could unlock the mysteries of COVID-19 – ModernHealthcare.com

Monday, April 27th, 2020

The team's results, posted as a preprint in BioRxiv earlier this month, proposed a handful of ACE2 variants suspected of boosting SARS-CoV-2 binding and, potentially, host susceptibility, along with several variants predicted to dial down ACE2 interactions with the viral spike protein that may be protective.

"What we can conclude is that this new virus has evolved new modality to interact with the ACE2 receptor," Jura noted. "Unfortunately, it seems like there are polymorphisms in the human population that will make some individuals more susceptible to binding this virus because these mutations are enhancing this unique part of the interface."

Seshagiri noted that such insights might make it possible to design potential therapeutic versions of ACE2 that are particularly adept at binding coronavirus spike proteins, thereby preventing the viruses from interacting with an individual's own ACE2 receptors, for example.

In a recent Cell paper, a team from Sweden, Spain, Austria, and Canada proposed its own strategy for engineering soluble, clinical-grade forms of the human ACE2 protein that appeared to dial down early-stage infections by SARS-CoV-2 in otherwise susceptible cell types.

"We are not the first to come up with the idea of saying ACE2 could be a therapeutic," he said, though he suggested that engineering soluble forms of the receptors protein that bind well to SARS-CoV-2 may serve as a strategy for "future proofing" against the emergence of these and other related viruses down the road.

The researchers plan to profile ACE2 polymorphisms in still more human samples for the final version of the study, which will likely be submitted for peer review in the coming weeks, Seshagiri said.

He and MedGenome CEO Rayman Mathoda noted that the diagnostic company, which is active in India and other emerging markets, is also a founding member of a GenomeAsia 100K project.

"We've made a very intentional effort to build on a data-focused set of efforts, where we take our proprietary data as we grow, but build in other data source," Mathoda said.

The investigators are not alone in attempting to establish a baseline understanding of ACE2 variation across and within populations.

At the University of Siena in northern Italy, Alessandra Renieri and her colleagues have been delving into ACE2 genetic variation using available exome sequences for some 7,000 healthy participants in the Network of Italian Genomes project. As they reported in a preprint posted to MedRxiv in early April, the investigators saw significant variation in ACE2 in that retrospective dataset, including both common and rare, missense variants predicted to influence the protein's stability and its interactions with the coronavirus viral spike.

"There is pretty wide genetic variability," Renieri said. "There are both polymorphisms, so variants found in a percentage of the population, and there are also rare variants a lot of rare variants."

It may be possible for the individual centers participating in the Network of Italian Genomes to recontact individuals in the future to try to find out who became infected with SARS-CoV-2 and to assess ACE2 variation alongside clinical outcomes, Renieri noted, though she cautioned that "ACE2 is just one of the many genes that could be involved."

For the reCOVID project, members of the team are seeking funding through the European Commission's Innovative Medicines Initiative IMI2 call for proposals to do functional analyses on ACE2 and other genes, for example, in the hopes of developing candidate therapeutics.

Renieri is also part of a team that been working since mid-March to prospectively collect samples from 2,000 COVID-19 patients at least 21 different hospitals in Italy as part of the GEN-COVID study, part of the COVID-19 Host Genetics Initiative.

For that project, researchers in Italy will use whole-exome sequencing to assess patient samples collected in conjunction with very detailed clinical information, she explained, while collaborators in Finland will genotype the samples for a related genome-wide association study.

See more here:
A gene that could unlock the mysteries of COVID-19 - ModernHealthcare.com

Read More...

Book review: ‘The Future is Faster Than You Think’ – Bowling Green Daily News

Monday, April 27th, 2020

The Future is Faster Than You Think: How Converging Technologies Are Transforming Business, Industries and Our Lives by Peter H. Diamandis and Steven Kotler. New York: Simon & Schuster. 2020, 384 pages, $20 (hardcover).

There is little doubt that the decade to come will be filled with radical breakthroughs and world-changing surprises, Peter H. Diamandis and Steven Kotler observe near the beginning of The Future is Faster Than You Think: How Converging Technologies Are Transforming Business, Industries and Our Lives, their exciting new treatise on what lies just around the corner and the impact it will have on everything.

As the chapters ahead make very clear, every major industry on our planet is about to be completely reimagined, they continue. For entrepreneurs, for innovators, for leaders, for anyone sufficiently nimble and adventurous, the opportunities will be incredible. It will be both a future thats faster than you think and arguably the greatest display of imagination rendered visible the world has yet seen. Welcome to an era of extraordinary.

As someone who has read a fair amount on what various thinkers have written about the wonders and pitfalls the future holds, I tend to be somewhat skeptical of these kinds of hyperbolic proclamations. In the present case, however, after making my way through this exquisite manuscript on where we currently find ourselves as a species, I have come to the conclusion their assessment is justified. We are indeed on the cusp of a revolution that will fundamentally change the world and how we function in it.

As might be expected given the nature of the subject matter, the book is exceptionally well-researched, with 76 pages of source notes at the conclusion of the foreword, 14 chapters and afterword that comprise the main text. Structurally, the content is arranged in three major sections: Part One, The Power of Convergence, consists of the first four chapters; Part Two, The Rebirth of Everything, is made up of the next eight chapters; and Part Three, The Faster Future, finishes out the narrative with chapters 13 and 14.

From my vantage point, Part Two constitutes the real meat and potatoes of their phenomenally insightful and intrinsically thought-provoking prose. The entire section is an interconnected description of what lies just over the horizon, as noted by the cascading chapters: The Future of Shopping, The Future of Advertising, The Future of Entertainment, The Future of Education, The Future of Healthcare, The Future of Longevity, The Future of Insurance, Finance, and Real Estate and The Future of Food. Embedded in these themes is an overarching nod to the future of work, something we all have a vested interest in from a more personal perspective.

As is usually the case with this kind of book, I was naturally drawn to how Diamandis and Kotler envision the tremendous technological innovations occurring at a breakneck pace and transforming education at all levels. Although I was a little apprehensive as I made my way through many of their arguments and the evidence they provided to support them, I was nonetheless encouraged by the optimistic tone that was unmistakable throughout their thesis.

Batch processing children is both an industrial hangover and an educational disaster because of basic biology, they explain in The Future of Education, the eighth chapter and one of my personal favorites for reasons previously indicated. Everyone is wired differently. Some of this is nature, some nurture, but the end result is the same: Were individuals, and theres no standard set of engaging experiences that can maximize learning for all.

But converging technology offers a host of new solutions to the challenges of quality and quantity, the authors continue a little later. Every technology thats currently making an impact on entertainment is doing double duty in education, meaning, as well see in a moment, one-size-fits-all is no match for the app store.

Lets just say I was not disappointed by the portrait they painted of the next phase in educations quickly-evolving manifest destiny.

Diamandis is founder and executive chairman of the XPRIZE, executive founder of Singularity University and the co-founder of Human Longevity Inc., Celularity and Bold Capital Partners. He has degrees in molecular genetics and aerospace engineering from MIT as well as an MD from Harvard Medical School. The founder of more than 20 high-tech companies, Fortune magazine named him one of the Worlds 50 Greatest Leaders in 2014. Kotler is founder and director of the Flow Research Collective as well as a best-selling author and award-winning journalist. His work has appeared in Time, The New York Times Magazine, The Atlantic, Wired and Forbes. His previous books include Stealing Fire, The Rise of Superman, Tomorrowland and Last Tango in Cyberspace.

In the final analysis, Diamandis and Kotler are realistic yet guardedly optimistic about the potential future thats within our grasp. They are not nave to the dangers that lie ahead, but they refuse to be paralyzed by them. In one sense, I interpreted their tome as a call to action an admonition to be more purposeful and rational in how we use the amazing tools we have at our disposal. Keeping the glass half full will take our collective commitment.

To be clear, there will still be terrorism, war and murder, they concede in the afterword. Dictatorship and disease wont go away. But the world will quietly continue to get better. The goal here isnt about creating a life of luxury, but rather a life of possibility. Thanks to the forces of convergence, the technological advances needed for that world of abundance are coming at an ever-increasing pace. Of course, creating that world wont happen automatically. It will still require the largest cooperative effort in history. And this brings us to our final question: What, exactly, are you waiting for?

I see that as a challenge none of us can afford to ignore. This was a very intriguing, sobering, enlightening and ultimately uplifting journey; highly recommended.

Reviewed by Aaron W. Hughey, Department of Counseling and Student Affairs, Western Kentucky University.

Read this article:
Book review: 'The Future is Faster Than You Think' - Bowling Green Daily News

Read More...

The Indian academic making the world look at flavours and food in a fresh way – The National

Monday, April 27th, 2020

If you are a foodie and love experimenting with flavours, how does a shrimp and egg salad sound for lunch? Or a tender juicy steak, just out of the oven, topped with a dollop of cheddar or Camembert, to be precise. And did you know mushrooms go smashingly well with nearly every common fruit, from apples to apricots and even coconut?

These food pairings may sound unappealing or at least unusual to most people, but Dr Ganesh Bagler of the Indraprastha Institute of Information Technology, New Delhi, says otherwise and he has the data and research to show for it.

Can we encode the intelligence of a chef into a computer, or can a computer fool a chef into thinking a recipe is real?

Akshay Malhotra

The computational gastronomy expert has taken the food and drink industry by storm with his ground-breaking work on flavour molecules and its corresponding database, FlavorDB.

His laboratory has also developed DietRX, an archive of nearly 2,000 foods, their chemical and genetic compositions, and their effect on health, which can enable culinary and drug interventions. (Ayurvedic diets are a historically important example of the belief in healing via appropriate foods.)

The power of data and food together is magic, says Bagler.

Already, chefs such as Garima Arora of Restaurant Gaa in Bangkok, are using Baglers research to fuel their own food experiments. What I find amazing about Baglers research is that his approach actually enables us to know exactly what makes up a cuisine the things that make Indian cuisine Indian, Arora, who is the first Indian woman with a Michelin star to her name, tells The National.

Once we have that knowledge, we can truly get to the main taste of a cuisine, which will help us do away with the flavours and ingredients we dont need.

Baglers work is also critical to Aroras Food Forward India, a non-profit initiative that aims to broaden the narrative around Indian food. It fits into the framework by being a forward-thinking initiative, one that serves the purpose of codifying a cuisine, and identifying, quantitatively, its identity, says project manager Matylda Grzelak.

Bagler, who is now considered the pioneer of computational gastronomy in India, credits curiosity for his success. Having studied various subjects from graduation through to postdoctoral studies quantum mechanics, computer science, computational biology, computational neuroscience and molecular genetics Bagler returned to India in 2010 following a stint at Berlins Max Planck Institute for Molecular Genetics.

He joined the CSIR-Institute of Himalayan Bioresource Technology at Palampur as a researcher, and worked on medicinal plants in the western Himalayas, and on diseases such as cancer and asthma. But it was not enough.

I like to explain things; Im a teacher, he says. This led him to the prestigious Indian Institute of Technology Jodhpur and finally IIIT-Delhi.

Bagler's foray into gastronomy happened when he came across a 2011 paper that took off from British chef Heston Blumenthals food-pairing hypothesis: foods that share flavour molecules will taste better together than those that do not.

For example, chocolate and blue cheese taste great together because they share 73 flavours (Blumenthals interest was piqued when he paired white chocolate and caviar, and hit the right notes). This led to companies such as Foodpairing, which present thousands of combinations of ingredients for chefs to experiment with.

Historically speaking, dishes have evolved over millennia from single-ingredient meals to complex ones, says Bagler. Cooking techniques and creative expression aside, why are some ingredients used together and others not? This was one of the critical questions that led Bagler to expand his research. Food science has been around, but it explored aspects such as the shelf life of foods or how to enhance sensory enjoyment. Now, people are looking at food from a data perspective.

What Bagler did differently was focus on Indian food, which he found is different from other cuisines because of the spices. Breaking down a collection of the late, celebrated Indian chef Tarla Dalals recipes, Bagler realised that spices form the basis of food-pairing in Indian cuisine. Having divided various foods into 26 categories vegetables, dairy, lentils, meats, etc he saw that mixing up items across all other sections did not cause too much of a shift in flavour, but when the spices were shuffled, the taste changed entirely.

Spices are the molecular fulcrum of Indian food

Dr Ganesh Bagler

For example, you could replace spinach with fenugreek leaves in palak paneer and there would not be much change in the dish, but if you replaced turmeric with cinnamon, the very essence of the preparation alters. Spices are the molecular fulcrum of Indian food, says Bagler.

In 2015, Bagler and his team of researchers sent this study to international science journals, which uploaded it to an open server where it was picked up by MIT Tech Review. This changed Baglers life. I only understood the academic value of this work, not its futuristic value, he says. It took me a year to understand that this had led to the creation of a new field of study, and now, over the past five years, Ive been developing the foundations of this area.

From 2,543 of Dalals recipes to nearly 158,000 global recipes, Baglers database has expanded exponentially. Not only is the data free to access on various websites and apps, but the information is also provided in excruciating detail, from the scientific names of elements to a comprehensive flavour network, possible pairings and health benefits. Bagler is also due to launch RecipeDB at a conference postponed amid the Covid-19 crisis where a massive collection of structured recipes will be available for everyone from chefs and cooking enthusiasts, to restaurateurs, multinationals and scientific organisations to use freely.

People know food technology, but they do not know about flavour technology, says Deepika Nadiminti, a flavourist at Mane India, which develops flavours for the dairy, confectionery and drinks industries. Baglers database is an all-in-one resource, where we can identify everything from flavour molecules to physical and chemical properties, and experiment easily, she says.

While Bagler consults for institutions such as the Indian Institute of Hotel Management and Symbiosis School of Culinary Arts, as well as a range of multinationals, chefs also swear by his research, which has significantly reduced time spent on developing new dishes, says Akshay Malhotra, a chef, food consultant and former student of the Culinary Institute of America.

FlavorDB will help us to understand the science behind Indian food, and it is only the beginning of how artificial intelligence will influence the food industry, he says.

This aspect is also key to Baglers future experiments. Can we encode the intelligence of a chef into a computer, or can a computer fool a chef into thinking a recipe is real? says Malhotra.

Can human creativity, which is at the heart of cooking, be reproduced using AI? It remains to be seen. For now, Malhotras observations pertain to FlavorDB complementing chefs instincts about pairing ingredients.

As celebrity chefs Manjit Gill and Akshraj Jodha describe Bagler's work, he is successfully quantifying the knowledge that, until now, was only intuitively available to a cook and everyone from chefs and diners to scientists will benefit from it.

Updated: April 25, 2020 04:57 PM

Go here to read the rest:
The Indian academic making the world look at flavours and food in a fresh way - The National

Read More...

Creighton’s Hereditary Cancer Center makes groundbreaking discoveries in cancer research – Omaha World-Herald

Monday, April 27th, 2020

Its difficult for Robin Farias-Eisner, M.D., Ph.D., to condense decades of cancer research into a single conversation. But recent developments call for brevity.

Sitting in his office on the second floor of the Hixson-Lied Science Building, Farias-Eisner, the newest director of Creighton Universitys Hereditary Cancer Center, explains how he and a team of researchers have discovered a new drug with the potential to treat a broad array of illnesses, including ovarian cancer, colon cancer, macular degeneration, heart disease and more.

It would be hard to overstate it, Farias-Eisner says of the potential impact of the find.

The research is one example of how the Hereditary Cancer Center is fulfilling its mission to pursue comprehensive research on all types of cancer. Established in 1984, the center is particularly devoted to cancer prevention through identification of hereditary cancer syndromes.

The center was founded by legendary cancer researcher Henry Lynch, M.D., a Creighton professor and pioneer in the field of cancer genetics. Prior to Lynchs research, prevailing medical thought held that cancer was primarily caused by environmental factors.

Through what doctors today call shoe-leather epidemiology, Lynch tracked down and interviewed cancer patients about their family histories, tracing the inheritance patterns of certain cancers through multiple generations. Researchers now estimate between 5% and 10% of cancers are inherited, according to the National Cancer Institute.

Lynch died at age 94 in June 2019. In July, the University named Farias-Eisner the new head of the Hereditary Cancer Center.

Farias-Eisner came to Creighton from the University of California, Los Angeles. There, as a surgeon-scientist, he earned a Ph.D. in molecular biology and ran his own laboratory specializing in womens cancer research.

My ultimate objective was to take care of women who had cancer, particularly gynecological cancers, because I felt that was an underserved population, Farias-Eisner says.

Through his lab work, Farias-Eisner and co-inventor, UCLAs Srinivasa Reddy, Ph.D., and a team of researchers identified a group of proteins that serve as early identifiers of ovarian cancer. The research led to the development of OVA1, a blood test that is currently being used worldwide to diagnose the disease.

Building on this work, Farias-Eisner, Reddy and a team of researchers developed HM-10/10, an artificial peptide that has been shown to be effective in inhibiting tumor growth in ovarian and colorectal cancers in mice.

In January, a paper detailing the research, Bovine HDL and Dual Doman HDL-Mimetic Peptides Inhibit Tumor Development in Mice was published as the featured article in the Journal of Cancer Research and Therapeutic Oncology. In addition to Farias-Eisner, the paper includes Holly Stessman, Ph.D., assistant professorin the Department of Pharmacology in Creightons School of Medicine.

This is a story of taking discoveries from the research bench and serendipitously arriving at a novel drug for use at the patients bedside, Farias-Eisner says.

The drug, Farias-Eisner says, has the potential to treat other pro-inflammatory diseases, a category which includes macular degeneration, heart disease, Alzheimers disease and endometriosis, among other clinically devastating diseases.

Prior to publishing on its effectiveness as a cancer treatment, Farias-Eisner and the team published another paper in the International Journal of Molecular Sciences showing HM-10/10s potential to treat retinal disease (e.g. macular degeneration).

The reason we wanted to publish in these two areas is to demonstrate the uniqueness of the drug and its clinical applications, Farias-Eisner says. Now that we have these two published papers, we can move toward clinical trials.

Creighton University offers a top-ranked education in the Jesuit, Catholic tradition and a welcoming, supportive environment to a diverse community of educators, professionals and support staff.Read moreabout the university, and connect with Creighton onFacebook,TwitterandInstagram.

Originally posted here:
Creighton's Hereditary Cancer Center makes groundbreaking discoveries in cancer research - Omaha World-Herald

Read More...

SHS grad involved in COVID-19 testing – SouthCoastToday.com

Monday, April 27th, 2020

SOMERSET When the Westborough based Integrated Genetics asked if any of its employees wanted to relocate to New Jersey for six weeks to do COVID-19 testing, Andrew Lanneville volunteered to go. He said it is a small contribution he can make to help during the coronavirus pandemic, but if he is needed, he is happy he can help.

"I wanted to do it," Lanneville said. "My family and friends and girlfriend have been very supportive of it. My employer has been gracious, always checking in on me, and the people down here are very grateful."

Integrated Genetics is a subsidiary of LabCorp Specialty Training Group. Lanneville, a 2008 graduate of Somerset High School, is a molecular biologist for Integrated Genetics. He is testing DNA samples from the sickest people in hospitals to determine whether they have COVID-19 or not. Lanneville said there are a lot of talented people from different places in the country who are working in the lab.

"People are here because they want to do their part, do what they can," Lanneville said in a telephone interview with The Spectator last Monday. "If they want to run molecular assays and DNA testing, I'm happy to do it and other people are happy to do it, as well."

Lanneville said 10,000 tests per day for COVID-19 were being done in the district in New Jersey where he was working. Last week, he said they were beginning a second method of testing that will take some of the burden off the instrumentation they are using so that they could double the amount of tests they were doing. He said the DNA samples don't just come from New Jersey, but also from New York and other places in the country.

In an article in The New York Times on April 13, the paper reported that the backlog for coronavirus testing in New Jersey was getting worse. At that time, the Times reported that New Jersey had conducted 115,000 tests, about one for every 75 residents. The newspaper article reported that the tests are a critical tool in measuring the disease's spread and a requirement for certain forms of treatment, yet they remain hard to get, and many people are actively discouraged from trying to get the tests. The article said that initially, the backlog was happening because there was not enough test kits, but said now there are not enough swabs and nurses. New Jersey has the second highest caseload of coronavirus cases in the country.

Another article in The New York Times on April 15 reported that, "The American Clinical Laboratory Association, a trade group representing large diagnostic companies like LabCorp and Quest, has recently reported a dip in the daily testing volumes of its members. On Monday, its members processed 43,000 tests, the lowest number since March 20. At one point in early April, members were processing more than 100,000 a day."

Lanneville said the people in the lab do not see the people who the samples come from. He said they don't even know their names. Each sample has a bar code to identify it to protect the identity of the person.

Lanneville said there are two types of testing done to determine if people have COVID-19. One is an antibodies test, which his company does not do. He said that test attempts to detect changes in immnune cells that are preparing to fight the virus. Lanneville said the problem with antibodies testing is that someone may be infected with the virus, but their body may not have changed to fight it yet, so it is possible to get false negatives. The other test, which his company uses, is a DNA test that directly detects the virus. It is called Polymerase Chain Reaction testing, which has been around since 1985. Lanneville said the test is based on a preliminary chain reaction that involves the COVID-19 being copied millions of times, if it is present in the sample from someone's body. He said the test takes a few hours to do.

"It's a little more involved," Lanneville said of the PCR test. "It's a little more technical. It takes a little more time."

Lanneville said sometimes the instrumentation being used to run the tests breaks down because it is being used so much to run samples.

Lanneville said the DNA test is more accurate than the antibodies test. He said reagants, that are like the on ramps and off ramps, are added to the DNA highway. The enzyme polymerase is the car that goes on and off the highway that replicates the viral DNA millions of times to confirm it's present. Lanneville said a process is gone through that can replicate viral DNA many times over if it is in the sample from the person's body. He said if there was COVID-19 in the person's body, there will be millions of copies of it. If the person did not have COVID-19, he said no copies are produced.

"It' very robust," Lanneville said of the PCR test. "It is very obvious who is positive for this virus and who is negative for it."

When Lanneville was interviewed by The Spectator over the phone last Monday, he had been at the lab in New Jersey for three weeks. He said when he first got to the lab, 30 to 32 percent of samples were testing positive for COVID-19, but those numbers rose to 35 to 36 percent. Lanneville said he does not think the increase is alarming because he says physicians are getting a better eye for who has symptoms of COVID-19, the flu or allergies.

Lanneville has worked in clinical laboratories for the last six years. He runs experiments that involve many people. Lanneville has a lot of experience running genetics based tests to see if there is a risk of passing on cystic fibrosis or other types of conditions to family members. He said his clients want more information about how that could affect the health of a child that is going to be born.

Lanneville said the COVID-10 DNA-based testing is a little different than what he usually does in terms of the setting and the patients, but he said the technology, equipment and theories behind the test are the same. He has been working 70 hours a week in the lab in New Jersey.

At Somerset High School, where he took Advanced Placement classes, Lanneville was involved in tennis, soccer, cross country and Model United Nations. After graduating from Somerset High School, Lanneville studied biology and economics at the University of Massachusetts at Amherst. While he is working, he is attending Boston College part-time to study business.

Asked about the risk of being infected with COVID-19 during the testing, Lanneville said, "At this point we are wearing surgical masks and protective face shields, along with gloves and labcoats. In addition, all COVID-19 samples (potentially positive or negative) are manipulated in a fume hood which has a negative pressure to essentially 'pull' the air out of the hood and also has a protective glass shield. There are some times when the samples are briefly exposed to the open air, when loading onto laboratory equipment, and there is no solution other than to minimize that time as much as possible."

"We have heard that another company performing testing in the area now has three technologists with COVID. There is some speculation that it may be due to the fact that the lab in question was manipulating samples in an open air environment. With all of the PPE needed at our disposal, I feel confident that risk of transmission is quite low. Honestly, I may have a higher likelihood of getting it from someone in the public areas of this building, outside of the lab, or the doorways of the hotel I'm staying at."

See more here:
SHS grad involved in COVID-19 testing - SouthCoastToday.com

Read More...

Mt. Sinai Hospital’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From FDA – The Jewish Voice

Monday, April 27th, 2020

Edited by: JV Staff

Several days ago, the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories received emergency use authorization from the U.S. Food and Drug Administration (FDA) for an antibody test that was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers and clinicians of the Icahn School of Medicine at Mount Sinai. This test detects the presence or absence of antibodies to SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) and importantly, may also be used to identify positive specimens with an antibody titer (level) up to a dilution of 1:2880 for the identification of individuals with higher antibody titers.

This important regulatory authorization reflects the success of a truly translational medical effort by our basic scientists, pathologists, and clinicians who have risen to the occasion and combined their unparalleled expertise in a way that will help the community at large as we fight this terrible disease, said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and President for Academic Affairs of the Mount Sinai Health System.

A research team led by Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, began working on the serologic test in January 2020, before COVID-19 had been seen in the United States. To make the test, the researchers used animal cells to produce copies of the telltale spike protein that is present on the surface of SARS-CoV-2. That protein is highly immunogenic, meaning that peoples immune cells see it and start making antibodies that can lock onto it. The test involves exposing a sample of blood to bits of the spike protein. If the test lights up, it means that person has the antibodies. Similar to the most commonly used tests for other viruses, such as hepatitis B, this test shows whether a persons immune system has come into contact with SARS-CoV-2.

Our test can pick up the bodys response to infection, in some cases as early as three days post-symptom onset, and is highly specific and sensitive, says Dr. Krammer. We have shared the toolkit needed to set up the test with more than 200 research laboratories worldwide to help mitigate this global crisis.

Once the research test had been developed in Dr. Krammers microbiology lab, Mount Sinais pathology and laboratory medicine experts were able to quickly transfer the technology to The Mount Sinai Hospitals Clinical Laboratories, which are certified by the Clinical Laboratory Improvement Amendments and accredited by the College of American Pathologists, signifying that the laboratory meets or exceeds industry standards for clinical laboratory testing. In this regulated laboratory environment, under the guidance of Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine, the test was validated.

Our microbiology colleagues generated great science and tools that were brought from the research lab into the clinical space to implement robust and compliant diagnostic tests with great specificity and sensitivity so that we can better care for our patients, says Dr. Cordon-Cardo. We are grateful to the FDA for granting this expanded authorization so that we can deploy this vital test to the community at large.

Under the leadership of David L. Reich, MD, President of The Mount Sinai Hospital, and Judith A. Aberg, MD, Chief of the Division of Infectious Diseases and Immunology in the Department of Medicine, The Mount Sinai Hospital became among the very first in the United States to initiate a convalescent plasma program on Saturday, March 28.

The exchange of ideas between clinicians and scientists and our intense drive to innovate is the catalyst that led to this achievement, says Dr. Reich. Mount Sinai will continue to advance the science and medicine in the fight against COVID-19.

Serologic testing for COVID-19 is a critical tool for helping us to understand the nature of the disease within our communities., says Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer of the Mount Sinai Health System. We continue to broadly partner this technology with industry, recognizing the need to scale serologic testing effectively.

Mount Sinais rich history and leadership in the fields of pathology, microbiology, and immunology helped to make this discovery and clinical application possible. From its beginnings in 1893, the Mount Sinai Department of Pathology, Molecular and Cell-Based Medicine has been a leader in the field. In addition to delivering more personalized pathology services to patients, Mount Sinai was the first major medical center to establish a fully integrated pathology department combining the various arms of testinganatomical, clinical, molecular/genetic, and cytologicalunder a single umbrella and now has the second largest department of its type in the nation.

The Department of Microbiology is led by internationally renowned microbiologist Peter Palese, PhD, who pioneered the field of reverse genetics for negative-strand RNA viruses, a revolutionary technique that is crucial for the study of the structure/function relationships of viral genes, for the investigation of viral pathogenicity, and for the development and manufacture of novel vaccines. It also has significant implications in understanding and preparing for infectious disease pandemics. Dr. Palese has recruited some of the top microbiologists in the world to study viruses and emerging pathogens. And the Division of Infectious Diseases is at the forefront of research, treatment, and prevention of infectious diseases with investigations focused on improving patient outcomes and rapidly translating research findings into patient care.

For inquiries related to commercial licensing of the test, please contact Cynthia Cleto from Mount Sinai Innovation Partners at: [emailprotected]

If you have recently recovered from COVID-19,see if you qualify for convalescent plasma transfusion.

To support COVID-19 research and response efforts, visit https://www.mountsinai.org/covid19research.

Continue reading here:
Mt. Sinai Hospital's Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From FDA - The Jewish Voice

Read More...

Drinking filtered brew coffee is the healthiest, says study – Free Press Journal

Monday, April 27th, 2020

London: We may all be drinking more coffee to help us survive the coronavirus (COVID-19) lockdown, and now researchers have revealed that filtered brew is the safest and healthiest one.

The study, published in the European Journal of Preventive Cardiology, examined links between coffee brewing methods and risks of heart attacks and death and found that coffee drinking was not a dangerous habit. In fact, drinking filtered coffee was safer than no coffee at all. The lowest mortality was among consumers of 1 to 4 cups of filtered coffee per day."Unfiltered coffee contains substances which increase blood cholesterol. Using a filter removes these and makes heart attacks and premature death less likely," said study author Professor Dag S Thelle from the University of Gothenburg in Sweden.

According to the researchers, experiments identified the culprit substances in coffee and found that they could be removed using a filter. A cup of unfiltered coffee contains about 30 times the concentration of the lipid-raising substances compared to filtered coffee.

Between 1985 and 2003, the study enrolled a representative sample of the Norwegian population: 508,747 healthy men and women aged 20 to 79. Participants completed a questionnaire on the amount and type of coffee consumed.

Data was also collected on variables that could influence both coffee consumption and heart diseases, so that these could be accounted for in the analysis. For example, smoking, education, physical activity, height, weight, blood pressure, and cholesterol.

Participants were followed for an average of 20 years. A total of 46,341 participants died. Of those, 12,621 deaths were due to cardiovascular disease. Of the cardiovascular deaths, 6,202 were caused by a heart attack.Compared to no coffee, the filtered brew was linked with a 15 per cent reduced risk of death from any cause during follow up.

For death from cardiovascular disease, the filtered brew was associated with a 12 per cent decreased risk of death in men and a 20 per cent lowered risk of death in women compared to no coffee. "The finding that those drinking the filtered beverage did a little better than those not drinking coffee at all could not be explained by any other variable such as age, gender, or lifestyle habits. So we think this observation is true," Thelle said.

The filtered brew was also less risky than the unfiltered beverage for death from any cause, death due to cardiovascular disease and deaths from heart attacks. "Our analysis shows that this was partly because of the cholesterol-increasing effect of unfiltered coffee," Thelle explained.

The researchers noted that unfiltered coffee did not raise the risk of death compared to abstaining from coffee - except in men aged 60 and above, where unfiltered brew was linked with elevated cardiovascular mortality.

Read more from the original source:
Drinking filtered brew coffee is the healthiest, says study - Free Press Journal

Read More...

Student Spotlight on Mika Matera-Vatnick ’21: Researching Insect Reproduction Genetics – Cornell University The Cornell Daily Sun

Saturday, April 18th, 2020

When Mika Matera-Vatnick 21 received President Martha E. Pollacks email in March announcing the closing of campus, her first thought was, What am I gonna do with my flies?

Matera-Vatnick, like many other undergraduate student researchers on campus, had to abandon her honors thesis research project as classes transitioned online for the remainder of the semester.

Last spring, Matera-Vatnick joined the Wolfner lab, led by Prof. Mariana Wolfner, molecular biology and genetics.

Research is the main thing Im involved with on campus. When Im not in class, Im in the lab, she said.

Currently, her research is on pause, since as of March 28, faculty and students are no longer allowed to work in laboratories, barring Matera-Vatnick access to laboratory equipment that is essential to the continuation of her research.

Matera-Vatnick is exploring the genetic basis of sperm competition in fruit flies the competitive process between sperm of two or more different males to fertilize the same egg during sexual reproduction.

Her passion for genetics started during a summer research experience at the bioethics department at the National Institutes of Health after her freshman year, where she learned about personalized medicine.

We are all unique with our own unique genomes and we need to treat patients based on their individual needs and their own genome. This is what led me to take the genetics and genetics lab courses at Cornell, she said.

Specifically, Matera-Vatnick is researching whether there are certain genes linked to mating plug ejection times.

Mating plugs are gelatinous secretions used in the mating in fruit flies and other species, including various primates such as kangaroos and reptiles. These secretions are deposited by a male into a female genital tract and later harden into a plug that glues the tract together. The plugs prevent females from re-mating, making it possible for females to store sperm.

In my experiments, Im comparing how long different strains of flies take to go through the process of mating plug ejection and seeing if there is a genetic basis and where in the gene this might come from, Matera-Vatnik said.

In fruit flies, the female expels the mating plug within five hours of mating in a process called mating plug ejection. The timing of ejection influences the paternity share of the fruit flys mates, playing an important role in mate competition.

Paris Ghazi / Sun Senior Editor

Matera-Vatnick experimenting in the Wolfner lab.

Matera-Vatnik randomly selected genetically diverse types of fruit flies to assess the time it takes for female fruit flies to undergo mating plug ejection. Mating plug ejection times can be compared to genetic variations across these specific fruit fly lines.

This comparison can reveal key genes associated with mating plug ejection, evolutionary histories of neural circuits and the role of these neuronal pathways in female sexual selection when a female chooses a male to mate with.

Understanding the process of sexual selection in insect reproduction may contribute to developing strategies for controlling pests and disease vectors in agriculture and public health.

Matera-Vatnick spent last summer at Weill Cornell Medicine in New York City learning about computational biology, which is the analysis of biological data through computer simulated models. In contrast to the work she did at WCM, Matera-Vatnick typically conducts her research on fruit flies in a wet lab. A wet lab is a lab where experiments are conducted and chemicals are handled, whereas in a dry lab, data is analyzed with computers and other technology.

Not much is known about the genetic basis that underlies the variations in mating plug ejection timing, but Matera-Vatnik is determined to find out.

I learned so much about how computational tools can be used to answer biological questions that are impossible to answer in a wet lab. I think that combining wet lab and computational power together will bring a unique angle to the questions Im interested in answering, she said.

Though research on campus has been put on hold, Matera-Vatnick is hopeful she can finish this project as her honors thesis.

This is the project that will be my senior thesis project. With all the uncertainty of being here, and hopefully the plan is to stay here over the summer, I want to take this project as far as I can before I graduate, Matera-Vatnick said.

Matera-Vatnick is currently in her hometown Washington, D.C. While she is unable to continue her research at the Wolfner Lab, she still attends weekly lab meetings and will be drafting sections of her honors thesis for the rest of the semester. She plans on taking the MCAT at the end of summer, if permitted.

In the meantime, Matera-Vatnick hopes to make the most of her Cornell research experience, upon her return to campus.

Im trying to take as much as I can from campus, Matera-Vatnick said. Thanks to amazing mentorship from my [Principal Investigator], graduate students and other students in the lab, I can say Im very lucky with who Ive surrounded myself with on campus.

Read the original here:
Student Spotlight on Mika Matera-Vatnick '21: Researching Insect Reproduction Genetics - Cornell University The Cornell Daily Sun

Read More...

Worldwide competition to find cure for COVID-19, other deadly viruses – WOGX

Saturday, April 18th, 2020

Great lab race to find cure for COVID-19

Researchers are trying to create and kill some of the most powerful viruses in the world in an ongoing competition.

Orlando, FL(FOX 35 Orlando) - Researchers are trying to create and kill some of the most powerful viruses in the world in an ongoing competition.

Youve heard of the space race, but did you know theres a race to find a cure for COVID-19? Dr. Paul Gulig, Department of Molecular Genetics and Microbiology at the University of Florida's College of Medicine says it's happening in several counties.

"Theres been discussion which tests were better," he says. "There can be an element of competition, almost sportslike and that is were in this altruistically. We generally want to help human health and mankind. At UF and around the world people are working on that."

He adds that when you have a limited resource like grant funding and the demand exceeds the supply, by definition, there is competition.

"We have to have a better grant proposal than the next person or theyre going to get the money and were not."

However, he says its not just about the money.

"Whoever comes up with the best things first is going to be able to come up with bragging rights."

But even with a race in research, he believes something positive has come out of this.

"Research scientists are banning together, I think theyre coming up with ways to collaborate that they havent before."

Dr. Michael Pape, professor of practice at the University of Central Floridas College of Business agrees, saying you can see the difference just by looking at ClinicalTrials.gov.

"There are 45 vaccine related clinical trials going on for COVID-19 and that is within two months. So youve got this type of contrast because of the pace of innovation, the ability to share information."

Continue reading here:
Worldwide competition to find cure for COVID-19, other deadly viruses - WOGX

Read More...

COVID-19: Hydroxychloroquine Does Not Work Better Than Standard Treatments in Trial – MedicineNet

Saturday, April 18th, 2020

APRIL 17, 2020 -- Hydroxychloroquine (HCQ) does not help clear the SARS-CoV-2 virus or relieve symptoms for COVID-19 patients more than standard care alone and has more side effects, a randomized controlled trial of 150 hospitalized adults in China suggests.

However, two experts caution that because of confounding, the trial is unable to answer convincingly the question of whether HCQ can benefit COVID-19 patients.

Wei Tang, with the Departments of Pulmonology and Critical Care Medicine at Ruijin Hospital, in Shanghai, China, and colleagues enrolled patients with COVID-19 from 16 treatment centers in China in February. They posted their findings on the medRxiv preprint server, but their paper has not been peer reviewed. A coauthor told Medscape Medical News the work has been submitted to a journal.

The overall 28-day negative conversion rate of SARS-CoV-2, which was the primary endpoint, was similar in the two 75-patient treatment groups. The Kaplan-Meier estimate for negative conversion rate was 85.4% in the HCQ plus standard of care (SOC) arm, vs 81.3% in the SOC-only group (P = .341). Negative conversion rates for the two groups were similar at days 4, 7, 10, 14, and 21.

Adverse events were reported in 8.8% of patients in the control group compared with 30% in the HCQ group. Diarrhea was the most common side effect, occurring in 10% of patients in the HCQ group vs none in the control group. Two patients in the HCQ arm had serious adverse events; one experienced disease progression, and the other experienced upper respiratory tract infection.

Patients in the HCQ group received a high loading dose of 1200 mg daily for 3 days followed by a maintenance dose of 800 mg daily for the remaining days. Total duration was 2 weeks for patients with mild or moderate disease and 3 weeks for those with severe disease.

No Difference in Relief of Symptoms

The two arms were similar in alleviation of symptoms by day 28: 59.9% with HCQ plus SOC vs 66.6% with SOC alone.

However, the researchers said that in a post hoc analysis, they found a significant reduction of symptoms after adjusting for the confounding effects of antiviral agents (hazard ratio, 8.83; 95% confidence interval, 1.09 71.3).

In addition, Tang and colleagues report a significantly greater reduction of C-reactive protein (CRP), a biomarker for inflammation, from baseline to day 28 in the HCQ group in comparison with the control group (6.986 vs 2.723 mg/L).

The authors suggest the alleviation of symptoms may come from HCQ's anti-inflammatory effects.

The mean age of the patients was 46 years, and 55% were male. Almost all patients had mild or moderate disease; two had severe disease.

Experts Say Study Arms May Not Have Been Comparable

J. Michelle Kahlenberg, MD, PhD, research professor of rheumatology at the University of Michigan in Ann Arbor, told Medscape Medical News that it's important to note that in the post hoc analysis, 89% of the patients in this trial were receiving other therapy in addition to HCQ.

"When [the researchers] say they saw improvement in symptoms when they removed the confounders, what they actually did was remove the patients from the analysis that got antivirals, and that left 14 patients in each arm," Kahlenberg said.

Moreover, Kahlenberg noted, 20% of patients who received HCQ had mild symptoms, whereas only 9% of those in the SOC group did.

"We don't know how those patients played out in the post hoc analysis whether it was the patients who were really mild that didn't get the antivirals that were left in the hydroxychloroquine group and that's why they had a slightly faster resolution of symptoms," she said.

She said that in this study, the researchers calculated CRP in milligrams per liter, whereas in the United States, it is measured in milligrams per deciliter. The conversion highlights the fact that the reduction in CRP was not terribly noteworthy, she said.

"The patients with COVID who tend to tank and have cytokine storms ? their CRP is much higher," she said. "So the small improvement in CRP wasn't that exciting.

"I don't think this gets us anywhere closer to an answer. It's another muddy study," she said.

Similarly, Christopher V. Plowe, MD, MPH, director of the Global Health Institute at Duke University in Durham, North Carolina, told Medscape Medical News he sees no convincing answers in this study.

Plowe, professor of medicine, molecular genetics, microbiology, and global health at Duke, also noted differences between the two groups at enrollment.

For example, the HCQ group had more than three times the number of patients with shortness of breath (22.1% vs 5.9%); more with sputum production (16.2 vs 5.9%); and more with cough (51.5% vs 38.2%). In addition, the average age was 4 years higher in the HCQ group.

"It makes me wonder whether the randomization was truly random," Plowe said.

Plowe also questioned the authors' statement that they didn't see cardiac arrhythmia events, such as prolonged QT intervals. "I can't see any evidence that they did an EKG on anybody," he said.

"This study leaves the door open to the possibility that hydroxychloroquine may have a clinical benefit. If there is a benefit, it seems to be related to the drug's anti-inflammatory properties. If that's the case, I'm not sure this particular drug, as opposed to others, would be the way to go," Plowe said.

Mixed Results in Other Studies

"Our negative results on the anti-viral efficacy of HCQ obtained in this trial are on the contrary to the encouraging in-vitro results and to the recently reported promising results from a non-randomized trial with 36 COVID-19 patients," the authors write.

However, the 36-patient trial to which they refer has since been called into question, as previously reported by Retraction Watch.

Despite lack of clear evidence of benefit, HCQ is recommended off label for the treatment of COVID-19 by the Chinese National guideline, and the US Food and Drug Administration has issued an emergency-use authorization for the treatment of adult patients with COVID-19.

By contrast, the Infectious Diseases Society of America recently concluded that because of insufficient data, they could not recommend any particular treatment for patients with COVID-19.

References

2020 WebMD, LLC. All Rights Reserved.

Original post:
COVID-19: Hydroxychloroquine Does Not Work Better Than Standard Treatments in Trial - MedicineNet

Read More...

How does a COVID-19 testing center look like? – The Times of Israel

Saturday, April 18th, 2020

The current time is unprecedented. We havent seen anything like this in the last ~100 years and (hopefully) wont see in the next 100 years. But, as a Ph.D. student in Molecular Genetics, it is moving to answer curious questions that people from non-scientific backgrounds might have regarding how coronavirus works and what can be done to slow it down.

In addition, I was fortunate enough to participate in the COVID-19 testing facility at the Weizmann Institute of Science, Israel. As the number of infections in Israel is going up, the facility at the Israel National Center for Personalized Medicine was commissioned to ramp the testing numbers. The center is one of the most sophisticated, top-of-the-line facilities, which can run ~4000 tests a day at its fullest capacity, while presently only 2500 tests are performed a day in Israel for a population of ~9 million. The idea of this article is to show how a COVID-19 testing facility looks like and take a step-by-step look at the operational pipeline.

A scheme of the operational pipeline for COVID-19 testing

Step 1 at Station A: The nasopharyngeal swab samples are received from hospitals/paramedical service in plastic tubes along with a document containing the patient information. Upon reception, each sample is cleaned and disinfected thoroughly with 70% ethanol and packed in a cooler box for internal transportation.

Team of volunteers at Station A (Image: Weizmann Institute of Science)

Step 2 at Station B: Here, hundreds of tubes are prepared, each containing a special kind of solution, called lysis/shield buffer. The genetic information of the SARS-Cov-2 virus (nCoV-2) is encoded by a molecule called RNA, which is a rather unstable molecule. The solution can stabilize the RNA molecule. It also contains a detergent that can inactivate the viral particles. Each of the tubes carries a unique barcode.

Step 3 at Station C: The swab samples from Station A and the buffer solutions from Station B are brought here. Station C is a biosafe room with biological hoods. These hoods are extremely sterile chambers, free from any biological contamination so that the technicians have minimal chance to come in contact with the virus. Each swab sample is manually inspected and added to the lysis buffer solution inside the hood. The barcode and the sample document are uploaded to an internal tracking software. The viral particles are inactivated from now on and can be handled with less stringency. The test tubes with the samples are then arranged in racks. The remaining swab sample from patients is returned to a fridge in order to be stored for at least 48 hours, in case a repetition of the test becomes necessary.

Step 4 at Station D: The racks (containing the sample in lysis buffer) from Station C are brought to Station D where an automated system can take a small volume containing the patient swab and put into a 96-well plate format. Such 96-well plates are routinely used in molecular biology approaches to detect nucleic acids (DNA/RNA).

Step 5 at Station E: In this station, a robotic liquid handler can assemble all the ingredients required for the subsequent chemical reactions. In the first reaction, the RNA from the virus is converted to its complementary DNA (cDNA) by an enzyme called reverse-transcriptase (co-incidentally, also first discovered in a virus). In the next reaction, the cDNA is acted upon by an enzyme (called DNA-polymerase that can work at high temperature) to produce multiple copies of a part of the cDNA by a process called polymerase chain reaction (PCR). The choice of the part of the cDNA is critical as it gives specificity to the detection of SARS-CoV-2, vis-a-vis other coronaviruses. The output of the test is typically in the form of a number (called, Ct) between 5-40, which is inversely related to the viral load in the patient. Thus, the lower the Ct, the more likely the patient is positive.

To increase the confidence in the test, two such regions of the nCoV-2 cDNA (N1 and N2) are chosen. For a test to be called positive, both N1 and N2 have to return a number below 40. More typically, the number hovers between 30 and 40 for positive cases. For negative cases, the numbers are above 40.

Step 6: In the last step, the data and corresponding patient ID are uploaded to the internal software and the final results are sent to the Ministry of Health.

All the stations are staffed with teams of 3-4 technicians while the entire operation is managed by a control center overlooking all stations and ensuring a smooth relay of materials and information between teams.

The team at the command center ensuring a streamlined operation (Image: Weizmann Institute of Science

Accuracy: RT-PCR based testing for the nCoV-2 virus is an extremely accurate test, with about a 3% chance of being falsely negative. Other than the operational steps, the false-negatives can arise from the presence of an extremely low amount of viral particles in the tested swab, below the detection limit of PCR. According to the US CDC, nasopharyngeal swabs are likely to yield the best results compared to swabs from other parts (nasal, oral, etc,)

What about scaling up?

In the present framework, all actions from Station D onwards (involving inactivated virus) are handled by automation, so it is relatively easy to scale up. However, all activities from receiving the samples to inactivating them are done manually under extreme care by trained professionals so as to minimize contamination of samples or spillage. Thus, it becomes one of the most time- and effort- consuming parts of the operation. Additionally, the collection of swabs is also done by trained front-line workers one-by-one, adding to the effective testing time. Thus, the rate-limiting step of the entire process becomes the collection and pre-processing of the samples, instead of the actual tests. The current end-to-end time (from the reception of the sample to delivery of results) is ~24 hours.

Further reading/watching:

Sandipan Dasgupta is a Ph.D. candidate at Weizmann Institute of Science, Israel and a co-founder of Weizmann Biotech Club. Previously, he was an Israel-Asia Leaders fellow at Israel-Asia Center, Jerusalem. He regularly blogs on India-Israel relations and is passionate about connecting global innovation ecosystems to India.Note: All opinions expressed are personal and are not endorsed by any affiliated institution or organization.

Read the original here:
How does a COVID-19 testing center look like? - The Times of Israel

Read More...

Why genetics is key to the evolution of aquaculture – The Fish Site

Saturday, April 18th, 2020

Many species of fish and shellfish have been domesticated relatively recently compared with most livestock species, and so have diverse gene pools with major potential for selective breeding, according to a new review paper in Nature Reviews Genetics.

The development of tools to gain insight into the genetics of these species, and apply such tools for breeding and management, provides opportunities to release that potential, researchers say.

Most aquaculture species can produce many offspring, and large populations with improved genetics can be bred quickly for improved production performance.

The benefits may include improved growth, resistance to disease or robustness in diverse farming environments.

Farmed fish is on course to overtake wild fish as the main source of seafood, and consequently genetic tools and expertise are in high demand to increase the efficiency and sustainability of aquaculture systems, which currently rely mostly on unselected stocks.

Insight into the genomes of species can enable careful selection of a farming population with desirable traits, and monitoring genomic variation will help maintain genetic diversity as farm populations develop.

In the future, technologies such as genome editing could be used to introduce desirable traits, such as disease resistance, into farmed species, and surrogate breeding could be employed to support production of preferred species.

The review paper a collaboration between experts from Universities of Edinburgh, Exeter, Stirling, and Aberdeen is an output of the AquaLeap consortium project.

AquaLeap is funded by the Biotechnology and Biological Sciences Research Council, the Natural Environment Research Council and the Scottish Aquaculture Innovation Centre, in partnership with the Centre for Environment, Fisheries and Aquaculture Science, Hendrix Genetics, Xelect, The National Lobster Hatchery, Tethys oysters, and Otter Ferry SeaFish.

Environmental biologist Dr Eduarda Santos, from the University of Exeter, who is the co-author of the study, said: "The rapid expansion of aquaculture has contributed to increased food security across the globe, however, issues related to domestication of desired species and emergence of diseases, limit its further development.

"Genomics has the potential to offer solutions to many of these limitations by improving our knowledge of the genomes of cultured organisms, genetic selection, and better understanding of the dynamic interactions between genes and the environment, to maximise food production."

Dr Jamie Stevens, also from the University of Exeter and co-author added: "We only have to look at the example of Atlantic salmon to see the immense value of a sequenced genome to the relatively recent optimisation of a wild species for the aquaculture market.

"Similarly, we anticipate the delivery of a genome for other species, including the European lobster, will offer similar opportunities to develop molecular tools with which to rapidly increase the potential of lobster as an aquaculture species and improve the sustainability of its wild populations."

Professor Ross Houston, from the Roslin Institute, agreed, saying: "There is a timely opportunity to harness the potential of farmed aquatic species, to ensure food security for a growing population. Genomic selection and biotechnology can speed up this process, and recent developments in these fields will soon be translated to benefit aquaculture production for many of these species across the world."

Originally posted here:
Why genetics is key to the evolution of aquaculture - The Fish Site

Read More...

New study suggests COVID-19 hopped from dogs to humans. Here’s why you should be skeptical. – Live Science

Saturday, April 18th, 2020

The novel coronavirus likely originated in bats, but the pathogen may have then hopped into dogs before infecting humans, a new study suggests.

But not everyone agrees with that hypothesis. One expert told Live Science that "there are a lot of weaknesses" in the study and that the data don't support the study's conclusions.

Before the new coronavirus SARS-CoV-2 made the jump to humans, two other coronaviruses, SARS-CoV and MERS-CoV, evolved in bats and passed through other animals on their way to people. SARS-CoV passed through civets and MERS-CoV through camels, and the molecular structure of SARS-CoV-2 suggests that the virus also passed through an intermediate animal, but scientists don't yet know which one.

In February, authors of a preliminary study published to the preprint database bioRxiv suggested that pangolins may bridge the gap between bats and humans, since SARS-CoV-2 and related coronaviruses that infect pangolins sport similar spike proteins a structure on the surface of the virus that allows it to infect cells. But other scientists argued that, despite their spike proteins, pangolin coronaviruses bear many differences to SARS-CoV-2 that make pangolins unlikely to be the source of infection, The New York Times reported.

With the mystery unresolved, biology professor Xuhua Xia of the University of Ottawa in Canada launched his own investigation into how the coronavirus passed from bats to people. His analysis, published April 14 in the journal Molecular Biology and Evolution, offered a new solution: dogs.

Xia reached his conclusion by scanning the genetic code of SARS-CoV-2 and other coronaviruses for a specific feature known as a CpG site, a sequence of genetic code in which the compound cytosine (C) is followed by the compound guanine (G). The human immune system sees CpG sites as a red flag, signaling that an invasive virus is present. A human protein called zinc finger antiviral protein (ZAP) latches onto the CpG sites on the viral genetic code and recruits help to break down the pathogen, according to UniProt, an online protein database. The theory follows that, the fewer CpG sites, the less vulnerable a virus will be to ZAP.

Related: 10 deadly diseases that hopped across species

Xia found that SARS-CoV-2 carries fewer CpG sites than the other known coronaviruses that first evolved in animals, including SARS-CoV and MERS-CoV. In addition, the closest known relative of SARS-CoV-2, the bat coronavirus RaTG13, contains fewer CpG sites than related bat coronaviruses, according to the analysis. "This suggests that SARS-CoV-2 may have evolved in a new host (or new host tissue) with high ZAP expression," which would place evolutionary pressure on the virus to shed CpG sites, Xia wrote.

Essentially, in order to survive and reproduce, a pathogen like SARS-CoV-2 needs to be able to evade the hosts immune fighters, and in this case it would mean getting rid of CpG sites that could alert ZAP proteins to the virus.

Unfortunately, little data exists on exactly how much ZAP appears in different animal tissues, Xia told Live Science. So he worked backwards, looking for animal coronaviruses with low CpG levels. He found a coronavirus that primarily infects the canine intestine, and thus inferred that the dog gut might contain adequate ZAP levels to drive viral evolution in this way.

"Only canids seem to have the tissue generating low-CpG CoVs during my study," Xia said. If a precursor to SARS-CoV-2 breached the canine intestine, then this would have "resulted in rapid evolution of the virus" to lose CpG sites and become better equipped to infect humans, he wrote in the paper. Beyond the low CpG levels, the paper did not note other genetic similarities between SARS-CoV-2 and the dog coronavirus, but suggested that the canine gut might provide the right environment for such viruses to evolve.

But why the dog intestine? Some research suggests that ZAP mRNA, which contains instructions to build the protein, appears in both the dog lung and colon but that higher concentrations accumulate in the lungs, Xia said. It may be that a glut of ZAP in the lungs guards the organ from coronaviruses, while the lower concentrations of ZAP in the colon leave the gut open to severe infection, though there are reasons to be cautious in coming to this conclusion, Xia said.

But does this hypothesis make sense?

"I think the data do not support these conclusions," Pleuni Pennings, an assistant professor of ecology and evolution at San Francisco State University, who was not involved in the study, told Live Science in an email. Pennings, whose research group has examined the CpG levels of many viruses, pointed out several weaknesses in the study's logic.

In a 2018 study published in the journal PLOS Genetics, Pennings surveyed CpG levels in the HIV virus and investigated how the pathogen evolves within individual people. She then led a similar study of several other viruses including Dengue fever virus, influenza, and hepatitis B and C to learn how often these bugs lose or gain CpG sites through mutations. Her group found that, in general, mutations that add CpG sites tend to be found in viral samples taken from people less often than mutations that remove CpG sites from the genome.

CpG-creating mutations may be costly to viruses in that they alert the body to infection, so over time, evolutionary forces minimize their appearance, Pennings said. That said, many viruses still carry CpG sites, so the mutations may carry some benefit "even if it comes with a slight cost," she added. So SARS-CoV-2 is not unusual in that way.

"There are many viruses with lower [CpG] values than SARS-CoV-2," Pennings said. "When you look at all viruses, the [CpG] value is not strange at all," she said.

Xia did find that SARS-CoV-2 contains fewer CpG sites than other animal-borne coronaviruses, and assuming that finding is correct, then it raises the question of why that came to be, she added.

But even if there is an evolutionary reason to explain why SARS-CoV-2 lost CpG sites, that evolutionary reason may not give the virus a special advantage for infecting humans, Pennings said.

In his paper, Xia noted that studies have "shown an association between decreased CpG in viral RNA genomes and increased virulence," meaning low-CpG viruses appear associated with more severe infection. However, although evolution favors mutations that delete CpG sites, and there's a general trend tying fewer CpG sites to more severe infection, "it doesnt mean that viruses with low numbers of CpG sites are necessarily more virulent," Pennings said. For example, the BK virus contains very few CpG sites and resides in the kidneys of an estimated 60% to 80% of adults, but typically only triggers symptoms in immunosuppressed people, she noted. (The virus was named the initials of the first person it was isolated from.)

If the CpG levels present in SARS-CoV-2 are somehow related to disease severity, "then this would provide an efficient way for vaccine development," Xia said. In this hypothetical scenario, scientists could eliminate CpG sites from the coronavirus genome in a lab dish, thereby weakening the bug to the point that it could safely be incorporated into a vaccine. But as of yet, no correlation has been drawn between CpG and the relative severity of SARS-CoV-2 infections.

Several pangolin coronaviruses included in Xia's study also contained few CpG sites, on par with SARS-CoV-2 and the bat virus RaTG13. Given other genetic differences between human and pangolin coronaviruses, however, the ancestor shared between this low-CpG pangolin coronavirus and SARS-CoV-2 would likely have existed over 130 years ago, Xia said. "We expect a SARS-CoV-2 progenitor to be much more recent," he said.

But did dogs serve as an intermittent host for the coronavirus? At this point, there's little evidence to suggest so.

Originally published on Live Science.

More here:
New study suggests COVID-19 hopped from dogs to humans. Here's why you should be skeptical. - Live Science

Read More...

No Hydroxychloroquine Benefit in Randomized COVID-19 Trial – Medscape

Saturday, April 18th, 2020

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Hydroxychloroquine (HCQ) does not help clear the SARS-CoV-2 virus or relieve symptoms for COVID-19 patients more than standard care alone and has more side effects, a randomized controlled trial of 150 hospitalized adults in China suggests.

However, two experts caution that because of confounding, the trial is unable to answer convincingly the question of whether HCQ can benefit COVID-19 patients.

Wei Tang, with the Departments of Pulmonology and Critical Care Medicine at Ruijin Hospital, in Shanghai, China, and colleagues enrolled patients with COVID-19 from 16 treatment centers in China in February. They posted their findings on the medRxiv preprint server, but their paper has not been peer reviewed. A coauthor told Medscape Medical News the work has been submitted to a journal.

The overall 28-day negative conversion rate of SARS-CoV-2, which was the primary endpoint, was similar in the two 75-patient treatment groups. The Kaplan-Meier estimate for negative conversion rate was 85.4% in the HCQ plus standard of care (SOC) arm, vs 81.3% in the SOC-only group (P = .341). Negative conversion rates for the two groups were similar at days 4, 7, 10, 14, and 21.

Adverse events were reported in 8.8% of patients in the control group compared with 30% in the HCQ group. Diarrhea was the most common side effect, occurring in 10% of patients in the HCQ group vs none in the control group. Two patients in the HCQ arm had serious adverse events; one experienced disease progression, and the other experienced upper respiratory tract infection.

Patients in the HCQ group received a high loading dose of 1200 mg daily for 3 days followed by a maintenance dose of 800 mg daily for the remaining days. Total duration was 2 weeks for patients with mild or moderate disease and 3 weeks for those with severe disease.

The two arms were similar in alleviation of symptoms by day 28: 59.9% with HCQ plus SOC vs 66.6% with SOC alone.

However, the researchers said that in a post hoc analysis, they found a significant reduction of symptoms after adjusting for the confounding effects of antiviral agents (hazard ratio, 8.83; 95% confidence interval, 1.09 71.3).

In addition, Tang and colleagues report a significantly greater reduction of C-reactive protein (CRP), a biomarker for inflammation, from baseline to day 28 in the HCQ group in comparison with the control group (6.986 vs 2.723 mg/L).

The authors suggest the alleviation of symptoms may come from HCQ's anti-inflammatory effects.

The mean age of the patients was 46 years, and 55% were male. Almost all patients had mild or moderate disease; two had severe disease.

J. Michelle Kahlenberg, MD, PhD, research professor of rheumatology at the University of Michigan in Ann Arbor, told Medscape Medical News that it's important to note that in the post hoc analysis, 89% of the patients in this trial were receiving other therapy in addition to HCQ.

"When [the researchers] say they saw improvement in symptoms when they removed the confounders, what they actually did was remove the patients from the analysis that got antivirals, and that left 14 patients in each arm," Kahlenberg said.

Moreover, Kahlenberg noted, 20% of patients who received HCQ had mild symptoms, whereas only 9% of those in the SOC group did.

"We don't know how those patients played out in the post hoc analysis whether it was the patients who were really mild that didn't get the antivirals that were left in the hydroxychloroquine group and that's why they had a slightly faster resolution of symptoms," she said.

She said that in this study, the researchers calculated CRP in milligrams per liter, whereas in the United States, it is measured in milligrams per deciliter. The conversion highlights the fact that the reduction in CRP was not terribly noteworthy, she said.

"The patients with COVID who tend to tank and have cytokine storms their CRP is much higher," she said. "So the small improvement in CRP wasn't that exciting.

"I don't think this gets us anywhere closer to an answer. It's another muddy study," she said.

Similarly, Christopher V. Plowe, MD, MPH, director of the Global Health Institute at Duke University in Durham, North Carolina, told Medscape Medical News he sees no convincing answers in this study.

Plowe, professor of medicine, molecular genetics, microbiology, and global health at Duke, also noted differences between the two groups at enrollment.

For example, the HCQ group had more than three times the number of patients with shortness of breath (22.1% vs 5.9%); more with sputum production (16.2 vs 5.9%); and more with cough (51.5% vs 38.2%). In addition, the average age was 4 years higher in the HCQ group.

"It makes me wonder whether the randomization was truly random," Plowe said.

Plowe also questioned the authors' statement that they didn't see cardiac arrhythmia events, such as prolonged QT intervals. "I can't see any evidence that they did an EKG on anybody," he said.

"This study leaves the door open to the possibility that hydroxychloroquine may have a clinical benefit. If there is a benefit, it seems to be related to the drug's anti-inflammatory properties. If that's the case, I'm not sure this particular drug, as opposed to others, would be the way to go," Plowe said.

"Our negative results on the anti-viral efficacy of HCQ obtained in this trial are on the contrary to the encouraging in-vitro results and to the recently reported promising results from a non-randomized trial with 36 COVID-19 patients," the authors write.

However, the 36-patient trial to which they refer has since been called into question, as previously reported by Retraction Watch.

Despite lack of clear evidence of benefit, HCQ is recommended off label for the treatment of COVID-19 by the Chinese National guideline, and the US Food and Drug Administration has issued an emergency-use authorization for the treatment of adult patients with COVID-19.

By contrast, the Infectious Diseases Society of America recently concluded that because of insufficient data, they could not recommend any particular treatment for patients with COVID-19.

The work was supported by the Emergent Projects of National Science and Technology; the National Natural Science Foundation of China; the National Key Research and Development Program of China; the Shanghai Municipal Key Clinical Specialty; the National Innovative Research Team of High-Level Local Universities in Shanghai; the Shanghai Key Discipline for Respiratory Diseases; the National Major Scientific and Technological Special Project for Significant New Drugs Development; and Key Projects in the National Science and Technology Pillar Program. The authors, Kahlenberg, and Plowe have disclosed no relevant financial relationships.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube. Have a tip for us? Contact us.

See the rest here:
No Hydroxychloroquine Benefit in Randomized COVID-19 Trial - Medscape

Read More...

UNM scientists get a better idea of where coronavirus started, how the spread will continue – KRQE News 13

Saturday, April 18th, 2020

ALBUQUERQUE, N.M. (KRQE) Where did a person in New Mexico get the coronavirus? How can we stop this from happening again? University of New Mexico scientists are trying to figure all of that out.

Using samples from people who tested positive for coronavirus, researchers are getting a better idea of where the virus started and how it will continue to spread. We can actually get an estimation on a total number of infections potentially in the state, says Dr. Darrell Dinwiddie, Assistant Professor at the Division of Genetics in the Department of Pediatrics.

UNM scientists are taking a closer look at the coronavirus. Those molecular clues, as we call them, are what gives us the ability to track how the virus is spreading, says Dr. Daryl Domman, Assistant Professor at the Center of Global Health. Those molecular clues are genomes. We compare the genetic sequences. The genome sequence of the virus were seeing in New Mexico, Dinwiddie says.

From that genetic sequence, they can determine how the virus were seeing here compares to stains around that nation, We can see if the early cases in New Mexico, for example, we can see that theyre similar to viruses that are coming out of New York or Europe that gives us the indication that they probably came from those places as well, Dinwiddie says.

They can also determine how the virus is entering and spreading in the community. If we see a cluster of samples that were six or seven samples and they all have the exact same genome sequence of the virus that suggests they all got infected within a week or two of each other potentially through a direct contact or a shared contact, Dinwiddie says.

Dinwiddie and Domman say so far, theyve tested 48 genomes from New Mexico and have 1,400 more ready for testing. Information for those tests tell them how long the virus has been spreading and what it might do next. This gives and empowers our public officials. They can make informed decisions on what needs to be implemented, Domman says.

By the end of the week, the research team expects to have some projections for how many more cases we could see in New Mexico. New Mexico is one of 19 states working with the CDC to generate the genome sequencing data.

Follow this link:
UNM scientists get a better idea of where coronavirus started, how the spread will continue - KRQE News 13

Read More...

Genomic mapping in outbred mice reveals overlap in genetic susceptibility for HZE ion and -rayinduced tumors – Science Advances

Saturday, April 18th, 2020

INTRODUCTION

Interplanetary space is populated by densely ionizing particle radiation not naturally present on Earth (1). Life on Earth has evolved under the protection of a geomagnetic field, which deflects high-charge, high-energy (HZE) ions; however, the constant flux of HZE ions in deep space is essentially impossible to shield, making astronaut exposures inevitable (2).

In the absence of human epidemiological data for exposures to HZE radiation, uncertainties surround the cancer risk estimates for space flight crews that venture beyond low Earth orbit. The current NASA space radiation cancer risk model is built largely upon epidemiological data from the survivors of the Hiroshima and Nagasaki atomic bombings, a cohort of individuals exposed predominantly to -rays (35), a form of photon radiation. One key assumption in this NASA model is that the spectra of tumor types, and their biologic behaviors, will be similar for individuals exposed to ionizing radiation, whether particle or photon. However, notable physical differences exist between ionizing photon and particle radiation, and these physical differences translate to unique ionization and damage patterns at the molecular, cellular, and tissue levels. HZE ion exposures produce spatially clustered DNA double-strand breaks, along with other DNA lesions in close proximity to break sites (6). In contrast, -rays produce sparse ionization events that are random in spatial distribution and less likely to have additional DNA lesions immediately adjacent to the break sites. Other assumptions in the model are that radiogenic tumors are no more lethal than their sporadic counterparts and that females are at greater risk for radiogenic cancers than males (7).

In assessing cancer risks to astronauts, the premise that HZE ion exposures increase the risk for the same types of tumors that arise in human populations exposed to -rays is supported by the few animal studies of HZE ion carcinogenesis conducted to date (8). These studies, conducted on genetically homogeneous animals, have demonstrated that tumor types arising in HZE ionirradiated animals are the same as those that occur spontaneously in these animals or following exposure to photon radiation (8). However, all previous data are from either inbred mice (9, 10) or rats (11), F1 hybrid mice (12, 13), or rat stocks with limited genetic heterogeneity (11, 1416), and the tumor types that arise in inbred rodents are determined, in very large part, by their genetic background. Therefore, the spectrum of tumors that might arise in a genetically diverse population exposed to HZE ions is unknown.

With the emergence of multiparent outbreeding strategies that produce highly recombinant mouse populations with allelic variants from multiple founder strains (1719), it is possible to model the effects of population diversity in carcinogenesis studies by minimizing the overwhelming effects of genetic background and increasing the phenotypic repertoire available within a test population. These populations also allow for high-precision genetic mapping (18, 20). Quantitative trait locus (QTL) mapping is a powerful forward-genetics approach that allows for unbiased testing of genetic variants that may influence gene-environment interactions for radiation effects (21, 22). Highly recombinant populations were constructed for the purpose of mapping complex traits, and QTL can often be resolved to megabase resolution (1820). In addition, complete sequence information can be used on genotyped individuals by imputing the substantial genomic resources available for the founder strains.

Studying tumors that arise in irradiated, genetically diverse mouse populations presents a unique opportunity to test key assumptions of the NASA risk model, particularly whether HZE ions induce the same tumors by the same mechanisms as -rays. If so, the current practice of extrapolating human epidemiological data from individuals exposed to -rays to astronauts exposed to HZE ions would be a valid approach for risk calculation in the space radiation environment.

To study the effects of HZE ion irradiation in a genetically heterogeneous population, 1850 HS/Npt stock mice (23) of both sexes were genotyped for 77,808 single-nucleotide polymorphism (SNPs) and exposed to (i) 0.4 gray (Gy) of 28Si ions (240 MeV/n) [linear energy transfer (LET), 80 keV/m; = 0.031 particles/m2] or (ii) 56Fe ions (600 MeV/n) (LET, 181 keV/m; = 0.014 particles/m2), (iii) 3 Gy of 137Cs -rays, or (iv) sham irradiation. We chose 56Fe ions because of their high abundance in galactic cosmic radiation (GCR) and because their high charge (Z = +26) makes them particularly damaging (24). The 28Si ions were selected because their LET more closely approximates the dose average LET of secondary fragments generated by GCR penetrating an aluminum spacecraft hull (25). The mice were monitored daily until they reached 800 days of age or became moribund. Comprehensive necropsies were performed on each mouse and involved all organ systems. Each detected lesion was characterized histologically by a board-certified veterinary pathologist. Tumors were the predominant cause of morbidity and mortality for both HZE ionirradiated (n = 622) and -rayirradiated (n = 615) populations as well as for the population of unirradiated mice (n = 613). Overall life span was significantly reduced for irradiated populations (Fig. 1A), which can be attributed to the increased incidence and decreased median survival for radiation-induced tumors. For irradiated mice, populations exposed to 0.4-Gy HZE ions had increased survival times compared to mice exposed to 3.0 Gy of -rays (Fig. 1A). Although these doses seem disparate, their selection is based on preliminary dose-response studies (26), which reveal that 0.4 Gy of HZE ions and 3.0-Gy -rays are each maximally tumorigenic.

Overall survival for HS/Npt mice, plotted as Kaplan-Meier survival, is presented for each exposure group (A). The incidence of specific tumor histotypes (B) and median survival times for these tumors (C) are plotted for each exposure group, which demonstrates that certain tumor types occur at an increased frequency following exposures to radiation of specific qualities and survival times in irradiated mice are decreased for some tumor types. The incidence of specific tumor histotypes within HS/Npt families is plotted for unirradiated (D), -rayirradiated (E), and HZE ionirradiated families (F) and demonstrates that specific tumor types often occur at very high incidence within some families and not at all in others, indicating heritability of tumor susceptibility. Furthermore, adjacent families are more closely related, and tumor incidences, for example, family 23 and adjacent families, have a high incidence of B cell lymphoma. The 47 HS/Npt families are arranged along the x axis (D to F).

A wide variety of tumor diagnoses [82 distinct tumor histotypes (table S1)] were observed in HS/Npt mice. Although most of these tumor types were rare, 18 histotypes were observed at incidences greater than 1%. Overall, the spectra of tumor histotypes produced in genetically diverse populations exposed to HZE ions and -rays were similar (Fig. 1B). Furthermore, tumor types induced by radiation were generally similar to those arising spontaneously in HS/Npt mice; however, radiation-exposed populations demonstrated decreased median survival times associated with tumor development (Fig. 1C and figs. S7 to S22) and increased incidences for specific tumor types, such as leukemias and Harderian gland adenocarcinomas, following radiation (Fig. 1B). The structure of the HS/Npt population can be divided into families that consist of mice more closely related to one another. Many tumor histotypes show high incidences within some families but are absent or rare in others (Fig. 1, D to F), which is consistent with genetic susceptibility to certain tumor types. Furthermore, certain tumorsparticularly lymphomas, pulmonary adenocarcinomas, hepatocellular carcinomas, Harderian gland tumors, and myeloid leukemiasdemonstrate a periodicity in tumor incidence (Fig. 1, D to F) where adjacent families often display similar incidences, which could be predicted on the basis of the circular breeding design used to generate HS/Npt, in which adjacent families are more related to one another than families further removed.

Although the tumor spectra are similar for each irradiated population, the different radiation qualities demonstrate varied efficiencies for producing specific tumor histotypes. -rayirradiated mice were at greater risk for myeloid leukemia, T cell lymphoma, pituitary tumors, and ovarian granulosa cell tumors than unirradiated mice; HZE ionirradiated mice demonstrated an intermediate susceptibility to these histotypes (Fig. 1B). For Harderian gland tumors, thyroid tumors, hepatocellular carcinomas, and sarcomas, HZE ion and -rayirradiated mice were at a similarly and significantly increased risk compared to unirradiated controls (fig. S7 to S22).

NASA permissible exposure limits for radiation limit the number of days an astronaut can spend in space based on modeled cancer risk. These limits are different for men and women (27) due primarily to epidemiological data that indicate that women are at greater risk for radiogenic cancers than men due to their longer life spans and susceptibility to specific cancer types, such as lung, ovarian, and breast carcinomas. Female HS/Npt mice have longer life spans than males (P = 2.7 106, log-rank test), with unirradiated females living 43 days longer (686.1 days), on average, than males (643.2 days) (fig. S1A). In contrast, no survival difference is observed between -rayirradiated females and males (P = 0.51) or HZE ionirradiated females and males (P = 0.06), indicating that female HS/Npt mice are more susceptible to radiation-induced morbidities and mortalities than males (fig. S1, B and C). Irradiated female mice had increased incidences of (i) ovarian tumors, (ii) mammary tumors, (iii) central nervous system tumors (pituitary adenomas, choroid plexus tumors, and ependymomas), (iv) diffuse large B cell and lymphoblastic B cell lymphomas, (v) osteosarcomas, and (vi) leiomyosarcomas (fig. S1D). Female mice were at lower risk for radiogenic lung cancer (fig. S1D and table S1), which is a major contributor to limiting flight time for female astronauts. Modeling risk by sex in humans has been confounded by different smoking rates between men and women in the atomic bomb survivor cohort (28).

To determine whether the genetic variants that increase tumor susceptibility following -ray irradiation also increase tumor susceptibility following HZE ion irradiation, genome-wide association mapping was performed for 18 tumor types in which there was an incidence of greater than 1%. Genomes were reconstructed for each mouse using a probabilistic model to predict founder haplotypes from high-density genotype data (18). Reconstructed genomes represent the unique accumulation of meiotic events for each individual and form a scaffold for the imputation of known sequencing information from the eight parental inbred strains. Polygenic covariance among related individuals is of significant concern in multiparent crosses and was corrected for during QTL mapping with a kinship term (18, 29). Mapping was performed for each phenotype using both a generalized linear mixed-effects model and proportional hazards regression model with the aforementioned kinship to adjust for polygenic covariance between related mice. To determine the significance thresholds for a model in which no QTL is present, the phenotypes were permuted, the regression model was run, and the maximum statistic was retained from each permutation (30). The 95% significance threshold was minimally variable between phenotypes with a mean threshold of log(P) > 5.8, and this value was used to identify significant associations. This is consistent with the estimated 0.05 Bonferroni genome-wide corrected threshold of log(P) > 6.0, which is considered overly conservative for QTL mapping (30).

At least one QTL was identified for 13 of the 18 tumor phenotypes examined. For tumor incidence, 35 QTL were identified with an average confidence interval of 3.4 Mb (table S2). For QTL at the 95% confidence threshold, effect sizes average 3.7% of the phenotypic variance with a range of 0.75 to 7.46%. For most of the tumors, the genetic architecture was complex with multiple QTL individually explaining a small proportion of the total variance. Although loci with moderate effects on the phenotype were most common, 11 large effect QTL were observed for seven tumor histotypes, with effect sizes greater than 5% (table S2).

To determine potential effects of genetic variants on tumor latency following irradiation, mapping was also performed using proportional hazards regression model (table S3) and 38 QTL were identified for 12 tumor types. QTL associated with tumor survival times mirrored those identified for tumor incidence, indicating that the genetic variants that control susceptibility to radiation-induced tumors also determine latencies.

Neoplasia is a binomially distributed trait, and therefore, the power to detect significant associations is primarily dependent on tumor incidence and QTL effect size. This leads to important considerations for the ultimate goal of this analysis, which is to determine similarities between QTL for specific neoplasms in populations exposed to different qualities of radiation. For some tumor types, a significant peak was observed in one exposure group with a suggestive peak present at the same locus in the alternative exposure group. We speculate that the reason certain radiation qualities produce only suggestive QTL for certain tumor phenotypes is likely due to decreased mapping power as a result of the variation in incidence between groups. In these cases, if the peak was more significant when combining radiation groups, the QTL was considered significant for all irradiated animals regardless of radiation quality.

Thyroid tumors are a well-known radiation-induced entity for both humans and mice; however, relatively little is known about genetic variants that increase susceptibility to this disease in mice. In HS/Npt mice, spontaneous thyroid adenomas occurred at relatively low frequencies and had a uniformly late onset, with tumors occurring between 700 and 800 days of age (Fig. 2A). In contrast, thyroid tumors arising in HZE ion or -rayexposed mice occur with significantly earlier onsets, with tumors arising as early as 250 days of age (Fig. 2A).

Thyroid follicular adenoma Kaplan-Meier survival estimate (A) along with genome-wide association plots for thyroid adenoma in HZE ionirradiated, -rayirradiated, HZE ion and -rayirradiated, and unirradiated mice (B) and an expanded plot for chromosome 2 (C), which contains the most significant association locus; gray lines indicate 95% (upper line) and 90% confidence (lower line) for log10(P values). Genome-wide association results reveal significant results in HZE ion and -rayirradiated mice that are further bolstered by combining the groups. The top panel of (D) shows strains that contribute the reference allele for the SNPs highlighted in red in the middle panel, indicated by vertical lines (D); the C57BL/6J strain contributes an allele that differs significantly from the other seven strains. The middle panel shows the log10(P value) of each SNP in the interval (D); the most significant SNPs are highlighted in red, and the bottom panel lists genes within the QTL interval. Genes that contain splice site, missense, or stop-related SNPs are colored red (D). Resample model averaging was performed within chromosome 2 to compare the distribution of peak log10(P values) for each exposure group (E); there is broad overlap for HZE- and -rayirradiated mice, and grouping all irradiated mice together further narrows the distribution of peak log10(P values). Mbp, megabase pair.

Association mapping reveals a significant 3.4-Mb interval on chromosome 2 for HZE ionexposed animals (Fig. 2, B and C). The same locus is identified in the -rayirradiated population if the significance threshold is decreased to a level at which 30% of identified QTL will be false positives. Combining both irradiated populations markedly increases the significance of the QTL identified on chromosome 2. The QTL interval (119 to 125 Mb) contains 39,179 SNPs (Sanger Mouse Genomes, REL-1505) and 142 genes (Ensembl version 85) (Fig. 2D). Within the QTL region, the C57BL/6J parental strain contains an introgression from the Mus musculus musculus genome (31); we found that HS/Npt mice carrying the C57BL/6J haplotype at the QTL have increased thyroid tumor incidence regardless of whether they are exposed to HZE ions or -rays.

To further explore the possibility that the QTL identified on chromosome 2 controls susceptibility following -ray and HZE ion exposures, we used a nonparametric resample model averaging procedure (32) across the entire chromosome to identify genomic loci that consistently reappear in resampled populations. Briefly, genome scans are repeated for each new dataset created, in which some individuals may be sampled more than once and some not at all (32). Resample model averaging consistently identifies the same locus for all groups of mice, regardless of radiation exposure (Fig. 2E). Furthermore, the resample model averaging procedure identifies the same locus for tumors arising spontaneously (Fig. 2E). Data from this tumor phenotype indicate that the same inheritable genetic variants contribute to an individuals risk of developing thyroid cancer, regardless of radiation exposure.

Acute myeloid leukemia (AML) is another common radiation-induced tumor in both mice and humans (33, 34). In concordance with previous studies conducted with inbred mice (26), -ray exposures in HS/Npt mice are more efficient at inducing AML than HZE ion exposures. In our -irradiated mice, 15.6% (96 of 615) developed AML compared to 2.9% (18 of 622) of those exposed to HZE ions and 1.6% (10 of 613) of unirradiated mice. AML median survival times were similar for all groups (Fig. 3A). Association mapping revealed a significant QTL for the -irradiated population on chromosome 2 that reached the 95% confidence threshold (Fig. 3, B and C), but no QTL was observed for the HZE ionexposed population, in which the incidence of AML was much lower. However, when grouping HZE ion and -rayirradiated mice together, the same QTL was significantly bolstered (Fig. 3B). If the susceptibility alleles identified at this locus were only contributing to disease following -ray irradiation and were, therefore, randomly distributed among the affected mice in the HZE ionexposed group, then we would expect the log10(P values) to decrease when combining -irradiated mice; however, the log10(P value) for this locus significantly increases when repeating the mapping procedure included all irradiated mice.

(A) Kaplan-Meier plots for myeloid leukemia demonstrate similar median survival estimates for myeloid leukemia between groups. (B) Genome-wide association procedures identify a narrow QTL on chromosome 2; two gray lines indicate 95% (upper line) and 90% confidence (lower line) for log10(P values). Expanded mapping results are depicted in (C) along with contributing strains for the reference allele. The A/J, AKR/J, C57BL/6J, DBA/2J, and LP/J strains contribute alleles that differ from the other strains, indicated by vertical lines in the top panel (C). The middle panel shows the log10(P value) of each SNP in the interval. The most significant SNPs are highlighted in red. The bottom panel shows the genes in the QTL interval. Genes that contain splice site, missense, or stop-related SNPs are indicated in red. Copy number results for Spi1 and Asxl1 in splenic samples from mice diagnosed with myeloid leukemia are plotted by exposure group (D).

Radiation-induced AML is a well-characterized disease in mice (10, 35, 36) and is most commonly the result of a radiation-induced minimally deleted region on chromosome 2 containing the PU.1 gene (current murine nomenclature, Spi1) and a recurrent point mutation that inactivates the remaining Spi1 allele (37). Figure 3C depicts mouse chromosome 2 with the positions of the QTL identified in our irradiated mice and the Spi1 gene. To test the hypothesis that AMLs occurring in HZE ionexposed animals will contain the same molecular aberrations know to occur in AML arising in -rayexposed mice, the copy number for Spi1 was investigated in leukemia samples to assess for deletions. As expected, most of the leukemias occurring in -rayexposed mice had a deletion in one copy of Spi1. In contrast, Spi1 deletions in spontaneously occurring AML were less common (Fig. 3D). Similar to -rayirradiated mice, leukemias that developed in mice exposed to HZE ions, although fewer in number, also have an increased incidence of Spi1 deletion. This finding indicates that AML arises by similar molecular mechanisms following exposures to HZE ions or -rays.

Because the QTL identified on chromosome 2 is approximately 60 Mb from the commonly deleted region containing Spi1 and because radiation-induced deletions can be notoriously large, we considered the possibility that the identified QTL was also deleted in these leukemias, resulting in loss of one copy of the QTL region. To test this hypothesis, we determined the copy number for a gene located at distal to the QTL support interval, Asxl1. As expected, we found that Asxl1 was not deleted in any sample in which Spi1 was not deleted; however, in 69% of cases with a Spi1 deletion, Asxl1and presumably the entire QTL regionwas also deleted (Fig. 3D). This demonstrates that most of the radiation-induced AML cases arose from progenitor cells haploinsufficient for the entire QTL region.

HZE ion and, to a lesser extent, -ray irradiation were particularly effective in inducing Harderian gland tumors at the doses used in this study, which was expected on the basis of extensive published radiation quality data on these tumors (8, 38). In the HZE ionirradiated group, Harderian gland tumors were observed in 22.7% (221 of 622) of mice and 3.2% (20 of 622) were malignant. In the -irradiated group, 15.3% (94 of 615) of mice developed Harderian gland tumors and 2.7% (17 of 615) were malignant. In contrast, spontaneous Harderian gland tumors occurred in only 4.1% (25 of 613) of unirradiated mice and 0.7% (4 of 613) were malignant. Despite the differences in tumor incidences following irradiation, median survival times for Harderian gland adenocarcinoma were similar for all groups (HZE ion, 582 days; -ray, 571 days; and unirradiated mice, 571 days).

Two QTL were observed for Harderian gland adenocarcinomas in HZE ionirradiated mice, one on chromosome 4 and another on chromosome 9 (Fig. 4A). The 1.7-Mb interval identified on chromosome 4 (Fig. 4B) is similar to previously discussed QTL regions in that combining both irradiated populations markedly increases the significance of this locus, which suggests that this QTL is associated with Harderian gland adenocarcinoma susceptibility in both HZE ion and -rayirradiated mice. In contrast, a 2.3-Mb QTL interval on chromosome 9 is observed only in HZE ionirradiated mice, and the locus is absent when combining all irradiated mice and repeating the mapping procedure (Fig. 4C). To further evaluate these QTL, resample model averaging was performed within chromosomes 4 and 9 to determine the distribution of peak log10(P values) along each chromosome. For chromosome 4, there is substantial spatial overlap identified in peak log10(P value) associations in the HZE ionexposed population and the -rayirradiated population, and the HZE ion and -rayirradiated population yields the most consistent identification of the QTL region (Fig. 4D). In contrast, although nearly all identified peak log10(P values) were identified in the 2.3-Mb QTL interval on chromosome 9 for HZE ionirradiated mice, the distributions of peak log10(P values) for other exposure groups do not substantially overlap and are widely distributed along the chromosome (Fig. 4E). The resample model averaging results indicate that while the chromosome 4 QTL contributes to susceptibility to Harderian gland adenocarcinomas in both HZE ion and -rayirradiated populations, the QTL identified on chromosome 9 appears to only be involved in Harderian adenocarcinoma susceptibility following HZE ion exposures.

Genome-wide association plots for Harderian gland adenocarcinoma (A) for HZE ionirradiated, -rayirradiated, HZE ion and -rayirradiated, and unirradiated mice; two gray lines indicate 95% (upper line) and 90% confidence (lower line) for log10(P values). Chromosome 4, which is expanded in (B), reveals a significant QTL associated with HZE ion irradiation, which is further increased significantly when grouping all irradiated mice (HZE ion and -ray irradiated) together, which indicated that the genetic variants in this location are important for Harderian gland adenocarcinoma following exposures to either HZE ion or -ray irradiation. In contrast, chromosome 9, which is expanded in (C), reveals a significant QTL associated only with HZE ion irradiation; this locus is absent when grouping all irradiated mice (HZE ion and -ray irradiated) together, which suggests that the allele(s) present in this region may only play a role for HZE ioninduced tumors. Resample model averaging was performed within chromosomes containing significant QTL. There is significant spatial overlap identified on chromosome 4 for peak log10(P value) associations in the HZE ionexposed population, the -rayirradiated population, and the HZE ion and -rayirradiated population that demonstrates the most consistent identification of the QTL region (D). In contrast, although nearly all identified peak log10(P values) were identified in the chromosome 9 QTL interval for HZE ion irradiated mice, the peak log10(P values) for other exposure groups are widely distributed along the chromosome (E).

In addition to looking for similarities between individual, selected QTL for HZE ion and -rayexposed populations, we also sought a more holistic method in which entire genome-wide association results could be compared between groups in an unsupervised process. We used hierarchical clustering to create cluster dendrograms using entire genome-wide scans for a given phenotype. By considering results from genome-wide associations, rather than individualized peaks observed within genome-wide associations, we submit for comparison not only highly significant QTL regions but also the numerous loci detected with lower confidence.

Unsupervised hierarchical clustering of genome scans creates significant clustering events that often occur for the same histotype regardless of radiation exposure (Fig. 5A). Multiple tumor histotypesincluding mammary adenocarcinoma, thyroid adenoma, and hepatocellular carcinomacluster by histotype, regardless of radiation exposure. To demonstrate and validate the methodology of QTL clustering, genome-wide scans for coat colors in each treatment group are evaluated and coat color genome-wide scans cluster together, as expected (Fig. 5B). These results further support the hypothesis that host genetic factors are highly important in determining risk of radiation carcinogenesis, whether following HZE ion or -ray exposures.

(A) Unsupervised hierarchical clustering of genome-wide association scans for tumor phenotypes reveals that the most significant clustering events often occur for the same histotype regardless of radiation exposure; these include mammary adenocarcinoma, thyroid adenoma, and hepatocellular carcinoma. (B) As expected, clustering genome scans for coat color demonstrates the expected results: that genome scans cluster together despite exposure group. The green line represents the 99% confidence level of the most significant dendrogram heights by permutations (log10 values permuted with genetic markers) to determine a distribution of dendrogram heights under the null hypothesis that no associations exist (C), demonstrating that the observed clusters are highly unlikely to occur randomly.

Permissible exposure limits for astronauts are based on the risk of death from cancer rather than cancer development, and the incidence to mortality conversion used in the risk calculation uses spontaneously occurring cancers in the U.S. population. Thus, there is an assumption that radiogenic tumors are no more lethal than spontaneous tumors. To determine whether tumors that arise following HZE ion exposure are more malignant than their counterparts arising in unirradiated or -rayirradiated mice, metastatic disease was characterized for each group. Pulmonary metastases were consistently observed in cases of hepatocellular carcinoma, Harderian gland adenocarcinoma, osteosarcoma, and ovarian granulosa cell tumor. Metastases were no more frequent in irradiated animals than in controls, and there was no significant difference in metastatic incidence between HZE ionirradiated mice and -rayirradiated mice (fig. S5A), and pulmonary metastatic density is similar between groups (fig. S5, B to D).

Tumor latency following irradiation was compared between exposure groups using survival statistics. Differences in tumor latency in this context indicate a decrease in time for tumor initiation or promotion. Since radiation is efficient at both initiation and promotion, decreased latencies are expected for irradiated population. Tumor progression is not evaluated, and our results therefore do not demonstrate whether tumors arising in irradiated individuals are more likely to progress rapidly than those arising spontaneously. As expected, tumors arising in both HZE ion and -rayirradiated mice show significantly decreased latencies in comparison to the unirradiated population (fig. S7 to S22). However, HZE ions did not further decrease latencies when compared to -rayirradiated mice.

Carcinogenesis as a result of space radiation exposure is considered the primary impediment to human space exploration (2). Compared to forms of radiation found naturally on Earth, including x-rays, -rays, and particles, HZE ions in space are much more difficult to shield (2) and have a distinct ionization pattern that aligns along dense track structures, resulting in clustered damage to chromatin (6). Because HZE ions, a highly penetrating component of GCRs, are not amenable to shielding (28, 29), exposure risks are inherent to manned missions in interplanetary space, but estimating the risk associated with this unique form of particle radiation is complicated by the essential lack of data for human exposures (28). As a substitute, human exposure data from other forms of ionizing radiation, primarily -ray (35) photon radiation, are used in cancer risk models with the assumption that photon and particle radiation have qualitatively comparable biological effects.

Animal models are a vital component in determining the validity of the extrapolation of human terrestrial radiation exposure data to exposures that will occur in astronauts in the space radiation environment. To date, carcinogenesis studies designed to evaluate the effects of HZE ions have used rodents with limited genetic heterogeneity (916). The advantage of removing genetic variability in animal models is the consequent decrease in phenotypic variability, which allows for fewer individuals to detect potential environmental effects on phenotype; the disadvantage is that strain-specific responses in genetically identical populations are significant and can obscure the variability that one might expect in a diverse population, such as humans. By using a genetically diverse population with a wide range of tumor susceptibilities, the spectra of tumors that occur following exposures to particle and photon radiation can be compared. The results of this study indicate that the spectrum of tumor histotypes observed in a genetically diverse population exposed to particle radiation is not unique to that observed in a population exposed to photon radiation or to the tumor spectrum observed in an unirradiated population. Despite the similarities observed in tumor spectra following radiation exposures, the radiation qualities and doses used for this study have unique efficiencies at producing specific tumor types, and while this work demonstrates that the underlying genetics of susceptibility can be similar for tumorigenesis following both high- and low-LET radiation, further work is necessary to define risks for specific tumor histotypes based on exposures.

This study uses a highly recombinant mouse population (HS/Npt stock) that is genetically diverse and designed for genome mapping (1921, 23), a forward-genetics approach that allows for an unbiased search of the entire genome for genetic associations. In contrast, genetically engineered mouse models rely on a reverse-genetics approach in which a given gene is first altered and the resulting phenotypes are then characterized. Studies using forward-genetics are most informative in populations that contain abundant genetic and phenotypic diversity. HS/Npt mice are a multiparent cross derived from eight inbred strains (A/J, AKR/J, BALBc/J, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J, and LP/J); each individual contains a unique mosaic of founder haplotypes and a high degree of heterozygosity, and recombination events become increasingly dense with each generation. Our population of HS/Npt mice was obtained from generation 71 of circular outbreeding. Creating these populations is not trivial and has been a central goal of communities involved in genetics research over the past few decades, resulting in the creation of rodent populations ideal for genome mapping (1820, 3942).

Genome mapping allows the discovery of QTL associated with susceptibility to complex traits, such as radiogenic cancers; this approach is uniquely suited to comparing inheritable risk factors for cancers following exposures to unique carcinogens, such as particle and photon radiation. In broader terms, this work demonstrates the utility of highly recombinant mouse models created for genetic mapping in carcinogenesis studies, an application that has not been previously attempted. Mapping QTL in carcinogenesis studies provides inherent challenges due to the structure of binomial data, potential confounding causes of death following irradiation and aging, the fundamental stochastic nature of radiation tumorigenesis, and incomplete penetrance of potential allelic variants. Despite these challenges, we were able to map QTL for 13 neoplastic subtypes and many of these identified loci are previously unidentified.

At the doses used in this study, HZE ions appear to be less effective than -rays in inducing precursor T cell lymphoblastic lymphoma (pre-T LL) and ovarian tubulostromal adenomas and granulosa cell tumors. This may be due to a combination of dose inhomogeneity in HZE ionirradiated tissues and the major role cell killing plays in the etiology of these specific tumors. pre-T LL can be prevented by transplanting irradiated mice with unirradiated syngeneic bone marrow cells or by shielding some of their bone marrow during irradiation (43, 44). The underlying mechanism by which unirradiated bone marrow cells suppress lymphomagenesis may involve a cell competition process by which older T cell progenitors resident in the thymus are normally replaced by fresh progenitors that immigrate from the bone marrow. Radiation kills these fresh bone marrow cells or reduces their fitness, which, in turn, prolongs the time that older T cell progenitors already in the thymus survive and self-renew. This, along with the increased proliferative cycles of the older T cell progenitors needed to maintain production of mature T cells, results in a corresponding increase in the oncogenic mutations that they accumulate and a concomitant increase in lymphomagenesis (45). Replenishing dead or damaged bone marrow cells by transplantation or preventing their damage through shielding suppresses lymphomagenesis.

At the 3-Gy dose of -rays used in this study, all of the bone marrow cells are uniformly irradiated. This is not the case for HZE particle radiation. The average diameter of a murine bone marrow cell nucleus is around 6 m (46). At the fluence of HZE ions used in this study, the probability that a 6-m-diameter nucleus will be traversed by a 28Si ion and a 56Fe particle is 0.88 and 0.40, respectively. On the basis of a Poisson distribution, the probabilities of a nucleus not being traversed at all are 0.41 and 0.67 for 28Si and 56Fe irradiation, respectively. Thus, many of the T cell progenitors in the bone marrow are not irradiated (although they receive a small dose from -rays). These cells should exert a protective effect similar to transplanting unirradiated bone marrow cells or shielding some of the bone marrow during irradiation, rendering HZE ions less efficient for lymphomagenesis. Given that most of the pre-T LL in the HZE ionirradiated group are likely spontaneous, it is expected that they cluster more closely to spontaneous pre-T LL than to -rayinduced pre-T LL.

The mechanism leading to murine tumors of ovarian surface epithelium origin is well understood. Loss of primordial follicle oocytes by radiation-induced apoptosis results in a decrease in estrogen production, which, in turn, leads to elevated levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in the circulation. FSH and LH drive proliferation of ovarian surface epithelium cells (47). Ovarian tumors can be induced in some animal models by artificially manipulating levels of these hormones (4749). Irradiated mice can be protected from tubulostromal adenomas and granulosa cell tumors by shielding one ovary during irradiation or by transplanting the mice with an unirradiated ovary (50, 51); these interventions protect some oocytes and thereby maintain proper regulation of FSH and LH levels.

Assuming that the target cells are primordial follicle oocytes with a diameter of 12 m, the probabilities of no traversals are 0.2 for 56Fe and 0.03 for 28Si at the 0.4-Gy dose used here. The probabilities for one or fewer traversals are 0.52 for 56Fe and 0.14 for 28Si. Whether a sufficient number of follicles survive at 0.4 Gy to account for the observed ovarian tumor sparing is unknown. Mishra and colleagues (52) observed a dose-dependent decrease in primordial stage follicles in C57BL/6 mice 8 weeks after irradiation with 56Fe ions (600 MeV/n). Sixteen percent of the follicles survived at the 0.3-Gy dose, and normal levels of serum FSH and LH were present; at 0.5 Gy, only 1% of the follicles survived and an increase in serum FSH was observed. Caution is needed in using Mishras results in interpreting our own since we used mice with different genetic backgrounds and the FSH and LH levels in the 0.3 Gyirradiated mice may increase relative to unirradiated controls if time points beyond 8 weeks are assayed. In any event, microdosimetric effects should be incorporated into any risk model for tumors in which cell killing plays a prominent role.

The location of the chromosome 2 QTL in a region frequently deleted in radiogenic AMLs may be happenstance, but there are scenarios in which its chromosomal location would be crucial to its function. One possibility is that the polymorphism increases the frequency of AML-associated chromosome 2 deletions in irradiated hematopoietic cells by controlling the spatial confirmation of the chromosome such that the proximal and distal deletion breakpoints are in close proximity to one another (46). This type of proximity mechanism has been evoked to explain recurrent chromosomal rearrangements seen in radiation-induced papillary thyroid carcinoma and some spontaneous cancers (53, 54). In this scenario, the QTL could be a structural polymorphism (e.g., segmental duplication or interstitial telomeric sequence), which would affect chromosomal conformation, yielding a different conformation in susceptible mouse strains than resistant strains. Structural polymorphisms are easily missed in the assembly of the strain-specific genomic sequences used for mapping studies, so we would be unaware of its existence. A second possibility is that the polymorphism is in a gene needed for myeloid progenitor cell survival. Mouse strains resistant to myeloid leukemia would have a hypomorphic allele of this gene. If one copy is lost (i.e., through radiation-induced deletion), then the remaining copy would be insufficient for cell survival. Thus, in mouse strains resistant to radiogenic AML, a chromosome 2 deletion, which is the first step in radiation leukemogenesis, is a lethal event and leukemogenesis is thereby halted. Susceptible strains would have a fully functional allele of the gene, so that if one copy is deleted, the remaining copy maintains cell viability, allowing further leukemogenic events to occur (46). A caveat to both the chromosome conformation and haploinsufficiency scenarios is that the chromosome 2 deletions mapped in radiogenic AMLs from the F1 progeny of AML-susceptible CBA/H mice and AML-resistant C57BL/6 mice do not occur preferentially in the CBA/H origin chromosome (55). However, in that study, only 10 tumors were informative. In addition, susceptibility to radiogenic AML is multigenic, so it is possible that the difference in susceptibility between the CBA/H and C57BL/6 strains is not due to the chromosome 2 QTL.

HZE ions seem particularly effective in inducing Harderian gland tumors at the doses used in this study. This result was expected on the basis of extensive published radiation quality data on these tumors (8, 38). The mechanism responsible for higher tumorigenic efficacy of HZE ions relative to -rays is unknown; however, we have identified a QTL associated with Harderian gland adenocarcinoma following HZE ion exposures that does not appear to lend susceptibility to the same tumor following -ray exposures (Fig. 4C). Furthermore, HZE ioninduced Harderian gland adenomas and adenocarcinomas cluster away from spontaneous and -rayinduced Harderian gland tumors (Fig. 5), indicating non-overlap of some of the susceptibility loci. There are data that suggest that HZE ion irradiation has an effect on tumor promotion that -ray irradiation lacks. The observation is that pituitary isografts, which result in elevated levels of pituitary hormones, enhance the induction of Harderian gland tumors and decrease their latency in mice irradiated with -rays or fission neutrons but do not increase tumor prevalence in mice irradiated with 56Fe ions (600 MeV/n) (12). This would explain the high relative biological effectiveness (RBE) for 56Fe ions. It would also render QTLs that act in the promotion of -ray and spontaneous tumors irrelevant to HZE ioninduced tumors.

The use of unsupervised clustering on genome-wide association results is a novel approach to search for shared tumorigenic mechanisms between radiogenic and spontaneous tumors or between tumors induced by different radiation qualities. Potentially, the results could be used to inform risk modeling. For example, using the 99% confidence interval as a cutoff, thyroid adenomas, pituitary tumors, osteosarcomas, B cell lymphoblastic leukemia, mammary tumors, and hepatocellular carcinomas cluster by histotypes regardless of whether they arose in HZE ionirradiated or -rayirradiated mice. Of these, the incidences of thyroid tumors, pituitary tumors, and osteosarcomas are significantly increased following exposures to either HZE ions or -rays. Taking pituitary adenoma as an example, these findings suggest that it would be reasonable to extrapolate the risk of HZE ioninduced pituitary adenoma as a multiple of -rayinduced pituitary adenoma risk (i.e., using a relative risk model). Because there were too few spontaneous pituitary adenomas to position them on the dendrogram, we cannot determine whether the risk of HZE ioninduced pituitary adenoma could reasonably be modeled on the basis of the incidence of the spontaneous tumor. Another pattern of association is observed for Harderian gland adenoma and follicular B cell lymphoma in which, at the 99% confidence interval, spontaneous tumors cluster with -rayinduced tumors but not with HZE ioninduced tumors. There are a number of ways that this could occur. Three possibilities are as follows: (i) HZE ions act through a tumorigenic mechanism different from that of spontaneous and -rayinduced tumors. (2) HZE ions bypass the need for one or more of the genetically controlled steps required for spontaneous and -rayinduced tumors, and (iii) there are multiple pathways to tumor formation, and HZE ion irradiation forces tumorigenesis through only one (or a subset) of them. Harderian gland tumors may fall into the second possibility. As described earlier, observations on mice receiving pituitary isografts before irradiation suggest that HZE ions may have Harderian gland tumor promotion effects that -rays lack. If so, the QTL controlling those effects would be inconsequential in the tumorigenesis of HZE ioninduced Harderian gland tumors, and those tumors would cluster away from their spontaneous and -rayinduced counterparts. Whether a relative risk model, an absolute risk model, or a combination of the two would be most appropriate in Harderian gland tumor risk calculations would depend on which of the above possibilities is most accurate.

NASA seeks to limit the risk of exposure-induced death (REID) from radiogenic cancer to below 3% (56). For multiple missions aboard the International Space Station (flown in solar minimum conditions), the model projects that males will exceed permissible exposure limits at 24 months and females, at 18 months; women are considered at greater risk for radiogenic cancers than men because of longer life spans and increased susceptibility to specific cancer types, including lung, ovarian, and breast carcinomas. Because the 3% REID is derived from the upper 95% confidence interval for the risk estimate (57), decreasing the uncertainty for space radiationinduced cancers can significantly increase the flight time allowed for astronauts. The 95% confidence interval surrounding the risk estimates not only primarily reflects uncertainties in our understanding of HZE ions but also includes uncertainties surrounding dose-rate effects, transfer of risk between human populations, space dosimetry, and errors in the existing human epidemiology data. Concerning sex predilections, our results also demonstrate a sex difference in carcinogenesis risk, where female mice are at greater risk for radiogenic cancers than males, following either HZE ion or -ray exposures. These results are consistent with the current NASA model to calculate cancer risk from space radiation exposures (5).

Whether genotypic assays of radiosensitivity can improve the precision of risk assessment in humans will depend on a number of factors. One is the extent to which heritable sequence variants determine cancer risk from HZE ion exposures. HZE ion radiation exposures result in more complex molecular lesions that are less amenable to repair (58). Thus, it could be argued that sequence variants that result in subtle differences in DNA repair and damage response pathways would have a lesser impact on HZE ion radiation carcinogenesis. However, this work demonstrates that genetic susceptibility does indeed have a significant role in tumorigenesis following HZE ion exposures. Personalized approaches to cancer risk assessments may eventually allow for greater reductions in uncertainties when generating space radiation cancer risk estimates (28).

There are limitations to a mouse carcinogenesis study comparing acute -ray and HZE ion exposures. First, for cost efficiency and logistics reasons, a single dose was used for each radiation quality: 3.0 Gy for -ray exposures and 0.4 Gy for HZE ion exposures. Preliminary studies have demonstrated that these doses produce the maximum tumor incidence in inbred strains (24). Because tumor susceptibility and association mapping were the primary goals of this study, doses were chosen with the goal of generating the greatest tumor incidences and, therefore, the greatest power to detect significant QTL. However, caution must be taken when comparing the two single-dose groups, as it is impossible to untangle dose responses in such a study. An additional benefit of the selected doses is that 0.4 Gy of HZE ions represents a realistic dose, received over 20 to 30 months, for a flight crew traveling to Mars. Second, the applicability of these findings to human populations is limited, as rodents serve only as models of carcinogenesis.

The results presented here indicate that host genetic factors dictate risk for tumor development following radiation exposures, regardless of radiation quality. Therefore, at a population level, risks can be extrapolated from terrestrial exposures to the space radiation environment and at an individual level, and humans harboring susceptibility alleles for radiation-induced tumors developed on Earth are also likely at increased risk in space.

Male and female HS/Npt mice (n = 1850) were generated from breeding pairs obtained from Oregon Health and Sciences University (Portland, OR). The mice were group-housed (five mice of the same sex per cage) in a climate-controlled facility at 70F (21.1C) with free access to food (Teklad global rodent diet 2918) and sterile water and a 12-hour light cycle. Mice were shipped to Brookhaven National Laboratories (Upton, NY) where they were exposed to accelerator-produced HZE ions at the NASA Space Radiation Laboratory at 7 to 12 weeks of age. HS/Npt stock mice of both sexes were exposed to 0.4 Gy of 28Si ions (240 MeV/n) (n = 308) or 56Fe ions (600 MeV/n) (n = 314), 3 Gy of 137Cs -rays (n = 615), or sham irradiated (n = 622). Following irradiation exposure or sham irradiations, mice were returned to Colorado State University (Fort Collins, CO) and monitored twice daily for the duration of the study. The mice were evaluated for cancer development until they reached 800 days of age or became moribund. All animal procedures were approved by the Colorado State University Institutional Animal Use and Care Committee.

This study uses a highly recombinant mouse population (HS/Npt stock) that is genetically diverse and designed for genome mapping (1921, 23). HS/Npt mice are a multiparent cross derived from eight inbred strains (A/J, AKR/J, BALBc/J, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J, and LP/J); each individual contains a unique mosaic of founder haplotypes and a high degree of heterozygosity, and recombination events become increasingly dense with each generation. Our population of HS/Npt mice was obtained from generation 71 of circular outbreeding.

DNA was isolated from tail biopsies taken from each mouse at 9 to 10 weeks of age. DNA was extracted and purified (QIAGEN, catalog no. 69506) according to the manufacturers instructions. GeneSeek (Lincoln, NE) performed genotyping assays using the Mega Mouse Universal Genotyping Array (MegaMUGA) (59) for a total of 1878 mice (including 28 inbred mice representing the founder strains). The MegaMUGA is built on the Illumina Infinium platform and consists of 77,808 single-nucleotide polymorphic markers that are distributed throughout the genome with an average spacing of 33 kb.

The heterogeneous stock mice are descendants of eight inbred founder strains. For each mouse, allele calls from the MegaMUGA array were used to calculate descent probabilities using a hidden Markov model (HMM), in which the hidden states were the founder strains and the observed data were the genotypes. The HMM generates probabilistic estimates of the diplotype state(s) for each marker locus and produces a unique founder haplotype mosaic for each mouse (18).

For this lifetime carcinogenesis study, all disease states were interpreted within the context of a systematic pathologic evaluation directed by board-certified veterinary pathologists (E.F.E. and D.A.K.). Structured necropsy and tissue collection protocols were followed for each mouse and involved photodocumentation of all gross lesions, collection of frozen tumor material, and preservation of tumor material in RNAlater. All tissues were grossly evaluated for all mice. To evaluate brain tissues and Harderian glands, craniums were decalcified for 48 hours in Formical-4 (StatLab, McKinney, TX 75069, product 1214) and five coronal sections of the skull were reviewed for each mouse. All gross lesions were evaluated microscopically and fixed in 10% neutral-buffered formalin and paraffin-embedded, and 5-m sections were stained with hematoxylin and eosin (H&E) and evaluated by a veterinary pathologist. For mice with solid tumors, all lung fields were examined histologically to detect the presence or absence of micrometastases. Tumor nomenclature was based on consensus statements produced by the Society of Toxicologic Pathology for mouse tumors (www.toxpath.org/inhand.asp). Representative histologic images routinely stained with H&E are presented in figs. S2 (A to E) and S3 (A and B).

Tissue microarrays were constructed to immunophenotype and subcategorize lymphoid neoplasms, which were the most commonly diagnosed tumors in irradiated and unirradiated HS/Npt mice. Identification of tissue sampling regions was performed by a veterinary pathologist. For each case, duplicate cores were taken from multiple anatomic locations (lymph nodes, spleen, thymus, etc.). Thirteen tissue microarrays were created, each of which contained six cores of control tissue at one corner of the array (haired skin, spleen, thymus, or liver); these control tissues were present in a unique combination and allowed for (i) orientation of the resulting sections, (ii) verification that the slide matched the block, and (iii) positive controls for immunohistochemistry. Figure S3D illustrates one tissue microarray as well as the resulting immunohistochemistry results for one thymic lymphoma (fig. S3E) and a core containing normal spleen (fig. S3F). Immunohistochemistry for T cell identification was performed using a rabbit monoclonal, anti-CD3 (SP7) antibody obtained from Abcam (ab16669; 1:300). Immunohistochemistry for B cell identification was performed using two rabbit monoclonal antibodies: an anti-CD45 antibody (ab10558; 1:1000) and an anti-PAX5 antibody (ab140341; 1:50). All immunohistochemistry was performed on a Leica BOND-MAX autostainer with the Leica BOND Polymer Refine Red Detection system (Leica DS9390, Newcastle Upon Tyne, UK). In addition to defining the immunophenotype, lymphomas were characterized according to the Mouse Model of Human Cancer Consortiums Bethesda protocols (60). For these protocols, anatomic location is important for the final diagnosis, and therefore, lymph node involvement was used from necropsy reports when necessary. Additional features included cell size, nuclear size, chromatic organization, and mitotic figure frequency, and the presence or absence of a leukemic phase was defined by bone marrow involvement within the sternum or femur. The most common lymphoma subtypes (fig. S4A) were evaluated for survival (fig. S4B), and pre-T LL typically presented with early-onset and large thymic masses.

Droplet digital polymerase chain reaction (ddPCR) was performed on cases of AML to assess deletion status via copy number variation for two genes: Spi1 and Asxl1. These genes are both located on chromosome 2 at base pair locations 91,082,390 to 91,115,756 for Spi1 and 153,345,845 to 153,404,007 for Asxl1. To establish a reference for normal diploid copy number in each AML sample, the copy number of H2afx was also determined. H2afx is located on chromosome 9, and deletions in this region have not been reported in murine AML. Bio-Rad PrimePCR probes were used for all assays as follows: Asxl1 ddPCR probe (dMmuCPE5100268), Spi1 ddPCR probe (dMmuCPE5094900), and H2afx ddPCR probe (dMmuCPE5104287). Ratios were created between the test gene and the reference gene (Spi1:H2afx and Asxl1:H2afx) to determine copy number with the assumption that the reference gene would not be deleted or amplified. Ideally, ratios of 1:1 represent equal copy numbers for both the test gene and the reference gene, and ratios of 1:2 represent a deletion in one copy of the test gene. However, since the tumor samples contained neoplastic cells as well as stromal cells and other cells, the ideal 1:2 ratio was not commonly observed. This is because stromal cells, which occur at unknown proportions in each tumor and which should not have chromosomal deletions, artificially increase ratios for tumor samples in which a deletion is indeed present. To account for stromal cell contamination, a cutoff ratio of 3:4 was established. Tumor samples with ratios below 3:4 were considered to have a deletion in one copy of the test gene.

For cases in which a solid tumor was identified, a standard section containing all lung lobes was processed and evaluated histologically. In cases where pulmonary metastases were observed, whole-slide scanning was performed at 200 magnification using an Olympus VS120-S5 and the OlyVIA software suite (www.olympusamerica.com/) to generate images for quantification of metastatic density (fig. S5). An analysis software, ImageJ (https://imagej.nih.gov/ij/), was used to quantify the total area of normal lung and the total area of metastatic foci (fig. S5). Metastatic density is reported as a percentage of the total metastasis area divided by the total lung area.

Association mapping was performed using a mixed-effects regression model with sex and cohort as fixed effects and a random-effects term to adjust for relatedness between mice by computing a matrix of expected allele sharing of founder haplotypes for each pair of mice (22). Three statistical models were fit to account for the wide range of trait distributions in this study. A generalized linear regression model was fit for binomial distributions, such as neoplasia. Cox regression analysis was incorporated to model time-to-event distributions to evaluate genetic contributions to tumor latency. Following genome-wide association analyses, resample model averaging methods were used to identify QTL that are consistently reproduced within subsamples of the mapping population.

Thresholds were determined using a permutation procedure in which the genotypes were fixed and the phenotype values were rearranged randomly within each sex. The distribution of the maximum negative log(P value) of association under the null hypothesis that no associations exist (null model) was determined for each genome scan with permuted data. One thousand permutations were performed for each phenotype in each radiation exposure group, simulating effects arising from covariates, the linkage disequilibrium structure of the genome, and effects due to phenotype distribution. A threshold was defined as an estimate of the genome-wide significance for which a type I statistical error will occur at a given frequency (29). Confidence intervals for each QTL were determined by nonparametric resample model averaging procedures using bootstrap aggregation with replacement. In this procedure, the mapping population is sampled to create a new dataset in which some individuals may be omitted and some may appear multiple times (30), and the locus with peak significance is recorded. Resampling is repeated 200 times for each phenotype to determine a 95% confidence interval for a given QTL. Effect sizes were calculated using the Tjur method for association mapping with logistic regression and pseudo-R2 for mapping with Cox proportional hazard regression. Statistical significance for each model was assessed using a permutation strategy to randomize genotypes via resampling without replacement and maintaining covariates. Permutation analysis was performed (1000 tests) for each trait and exposure group to generate estimations of genome-wide significance thresholds. As genome scans with hundreds of thousands of imputed SNPs are computationally intensive, parallel computing was essential and accomplished using spot instances of resizable Elastic Compute Cloud hosting resources.

Comparisons were made between whole-genome scans using Pearson correlations as a similarity measure with clustering based on average linkage. Significance of clustering results was estimated with 10,000 random permutations of the dataset (log10 values permuted with genetic markers) to determine a distribution of dendrogram heights under the null hypothesis that no associations exist. Each permutated dataset simulates a null distribution of the maximally significant clustering based on a randomly assorted set of P values for each genomic locus.

Bootstrap aggregation is a resample model averaging procedure that has been demonstrated to produce highly accurate estimates of QTL in structured populations (32). The procedure is relatively simple: for a genome-wide association study (GWAS) of n individuals, a sampling of n draws is obtained, with replacement, from the observed individuals to form a new dataset in which some individuals are omitted and some appear multiple times. For each new dataset created this way, an estimate of the QTL location is calculated. This process is repeated many times and is the basis for determining a confidence interval for a given result. The use of bootstrap procedures is commonly used this way to estimate QTL support intervals in experimental crosses; however, this statistical method can potentially be applied to other areas of QTL research, including comparative QTL mapping.

When an identical QTL is observed for two distinct traits, one explanation is that a single gene is involved for two distinct biologic processes, also known as pleiotropy. This was sometimes assumed in early mouse QTL studies that resulted in coincident loci for distinct traits. Another possibility, however, is that two distinct genetic variants are present in close proximity, each independently contributing to the two phenotypes. Because the two hypothetical genetic variants happen to be in close proximity, they are difficult to distinguish in low-resolution mapping studies. Using resample model averaging in highly recombinant mice is proposed to best differentiate precise locations of the QTL; if the same markers were repeatedly identified, then the case for pleiotropy was strengthened. For comparative QTL mapping in tumorigenesis studies, nonparametric resample model averaging could similarly be leveraged to identify whether the same QTL renders an individual susceptible to distinct environmental carcinogens. One significant advantage to using bootstrap procedures to detect potential coincident loci is that comparisons can be made between groups based on the identification of a highly significant QTL identified in only one exposure group (e.g., at a false-positive rate of 1 per 20 scans). This QTL may be present in the alternative exposure group, but at lower confidence (e.g., at a false-positive rate of 1 per 10 scans), and therefore discarded in a typical GWAS. A diagrammatic representation of the comparative QTL bootstrap procedure is presented in fig. S6. Because the resultant genetic positions derived from bootstrapping are composed of the most significant locus for each resampling regardless of the significance level for the mapping procedure, comparisons can be drawn between QTL that might have been discarded on the basis of the stringent statistical demands of an assay involving hundreds of thousands of independent tests. Using this procedure on thyroid tumors demonstrates that the same loci are consistently identified whether exposed to particle or photon irradiation (Fig. 2E). Using the comparative QTL procedure described, it can be determined whether an individuals cancer risk from one carcinogen will be predictive of that individuals cancer risk to another carcinogen. The application of this procedure is well illustrated by the space radiation problem, where much is known about -ray exposures and little is known about space radiation exposures.

In addition to looking for similarities between individual selected QTL for HZE ion and -rayexposed populations, we also sought a more holistic method in which entire genome scans could be compared between groups in an unsupervised process. By using entire genome scans, we submit for comparison not only highly significant regions but also the numerous loci detected with lower confidence. To determine similarity of genetic association profiles for all phenotypes and to detect possible coincident QTL, clustering procedures were used to compare genome-wide association scans between different radiation exposure groups. To demonstrate and validate the methodology of QTL clustering, genome-wide scans for coat colors in each treatment group are evaluated (Fig. 5B). As expected, genome-wide scans for coat color are unaffected by radiation exposures, and therefore, clustering is based entirely on coat phenotype rather than radiation exposure group. Using the same procedure for neoplasia indicates that tumor types often clustered together as well, regardless of radiation exposure (Fig. 5A). Genome scans for thyroid tumors and mammary adenocarcinomas in radiation-exposed groups and all hepatocellular carcinoma genome scans cluster together. This finding supports the hypothesis that host genetic factors are more important in determining neoplasm incidence than radiation exposure type. Unlike other statistic procedures, such as regression models, clustering lacks a response variable and is not routinely performed as a formal hypothesis test. Therefore, determining the significance of a clustering result can be problematic, as no consensus method exists for cluster validation. Permutation analysis provides the distribution of clustering results that will randomly occur from a given dataset; this can then be used as a baseline from which to determine a significance level on a given dendrogram tree [green line in Fig. 5 (A to C)]. While the overall validity of a given cluster can be accomplished by cluster permutation analysis, no method is identified to estimate the number of clusters that should be present in a dataset. Furthermore, methods to determine the significance of specific subset of objects clustering together do not exist; in such cases, the permutation threshold is likely overly stringent.

See more here:
Genomic mapping in outbred mice reveals overlap in genetic susceptibility for HZE ion and -rayinduced tumors - Science Advances

Read More...

Page 18«..10..17181920..30..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick